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Chapter 1 
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Alzheimer’s Disease 
 
 
The pathology of Alzheimer’s Disease (AD) is the most common form of 
dementia characterized by a progressive neurodegenerative disorder affecting the 
elderly that cause a slow insidious decline in cognitive ability, with an eventually fatal 
deadly outcome. 
An estimated 10 percent of Americans over the age of 65 and half of those over 
age 85 have AD. More than four million Americans currently suffer from the disease, 
and the number is projected to balloon to 10-15 million over the next several decades. 
Alzheimer's Disease is now the third most expensive disease to treat in the U.S. The 
annual national direct and indirect costs of caring for AD patients have been estimated 
to be as much as $100 billion. People with AD live an average of 8 years after 
diagnosis, but may survive anywhere from 3 to 20 years. 
This pathology has no known single cause, but in the last 15 years scientists have 
learned a great deal about factors that may play a role. Late-onset AD, which chiefly 
affects individuals over age 65, is the more common form of the illness that is most 
often associated with the term “Alzheimer’s disease.” The greatest known risk factors 
for late-onset AD are increasing age and a family history of the disease. The likelihood 
of developing late-onset AD approximately doubles every five years after age 65. By 
age 85, the risk reaches nearly 50 percent.  Scientists have so far discovered one gene 
that increases risk for late-onset disease. Rare, familial types of AD found in a few 
hundred families worldwide have been linked to specific genes. Individuals who inherit 
these genes are virtually certain to develop the disease, usually before age 65, and 
sometimes as early as their 30s or 40s. This is a rare form of AD known as early-onset 
familial AD. 
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Researchers are working to discover other factors that affect AD risk. Some of the 
most exciting preliminary evidence suggests that strategies for general healthy aging 
may also help reduce the risk of developing AD. These measures include controlling 
blood pressure, weight and cholesterol levels; exercising both body and mind; and 
staying socially active. 
Presently, researchers cannot definitively say what causes Alzheimer’s disease, 
and there is currently no cure. However, considerable progress has been made in the 
field of AD research in recent years, including the development of several medications 
for early-stage AD. While the ideal medication for AD would either prevent or cure it, 
have no side effects, be inexpensive and be readily available, researchers have not yet 
discovered the ideal treatment. It is possible, however, to reduce some of the common 
symptoms of early-stage AD with medications. As of January 2002, the Food and Drug 
Administration (FDA) had approved four drugs designed to improve memory and slow 
the progression of AD. The first one, approved in 1993, Tacrine (Cognex ®)  in Figure 
1.1 has many side effects, including potential liver damage and has shown disappointing 
memory results. For these reasons it is seldom prescribed. Three newer drugs (Figure 
1.1), Donepezil (Aricept ®), Rivastigmine (Exelon ®) and Galantamine (Reminyl ®), 
have proved beneficial in improving memory, and have fewer side effects. 
Unfortunately, these drugs are not effective for everyone, and their effectiveness is 
limited to the early and middle stages of AD. Another drug, Memantine HCl 
(Namenda® in Figure 1.1) is available.  
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Originally considered for use in moderate to severe stage AD, it is sometimes 
prescribed for use earlier. None of the therapies currently available offer significant 
benefits in terms of slowing the progression of the disease. All can be considered be 
largely “symptomatic” treatments as opposed to “disease modifying”. 
 It currently is also possible to reduce some of the common emotional and 
behavioral symptoms associated with AD. For example, it is possible to prescribe drugs 
such as tranquilizers to reduce agitation, anxiety and unpredictable behavior. Drugs also 
can be prescribed to improve sleeping patterns and treat depression. Physicians may 
recommend taking Vitamin E, which may have some positive effects without unwanted 
side-effects if taken in reasonable quantities. 
In the popular imagination AD is equated with an impaired memory, but the 
disease includes a number of other changes in brain function ; experts have documented 
common patterns of symptom progression that occur in many individuals with 
Alzheimer’s Disease and developed several methods of “staging” based on these 
patterns. Progression of symptoms corresponds in a general way to the underlying nerve 
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cell degeneration that takes place in AD. Nerve cell damage typically begins with cells 
involved in learning and memory and gradually spreads to cells that control every 
aspect of thinking, judgment and behavior. The damage eventually affects cells that 
control and coordinate movement.  
From the histological point of view the earliest damage occurs in the entorhinal 
cortex, hippocampus and basal forebrain, which are small, specialized structures in the 
brain that play a critical role in memory. The most striking early symptom is, in fact, 
loss of short term memory (amnesia), which usually manifests itself as minor 
forgetfulness that becomes steadily more pronounced with illness progression, with 
relative preservation of older memories. As the disorder progresses, cognitive 
(intellectual) impairment extends to the domains of language (aphasia), skilled 
movements (apraxia), recognition (agnosia), and those functions (such as decision-
making and planning) closely related to the frontal and temporal lobes of the brain as 
they become disconnected from the limbic system, reflecting extension of the 
underlying pathological process.  
 
Figure 2.1: Neurofibrillary Tangles and Amyloid  Plaques 
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From the clinical point if view, AD overlaps with many other conditions leading 
to dementia. Advanced age in particular makes accurate diagnosis difficult if not 
possible.1 2 3 4 Even at necropsy, macroscopic examination of AD brains again shows an 
extensive overlap with changes encountered in normal aging. Thus, at the present, AD 
can be diagnosed positively only at necropsy on microscopic examination using silver 
impregnation stains, amyloidophilic dyes, or antibodies for visualisation. 
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The Pathology of Alzheimer’s Disease 
 
 
 
The pathology must take precedence, and in terms of pathology, the common 
theme of aberrant protein deposition is emerging with respect to a number of different 
neurodegenerative diseases such as Parkinson’s disease (Table 1), Huntington’s disease, 
prion diseases and amyotrophic lateral sclerosis (ALS, Lou Gehrig’s disease)(Table 
1.1). 
In Parkinson’s disease, neuronal deposits called Lewy bodies containing R-
synuclein are found in the substantia nigra, the subregion of the brain in which 
dopaminergic neurons are selectively lost. In Huntington’s disease, the mutated 
huntingtin protein possesses a long string of glutamates that leads to the formation of 
intracellular inclusions in disease-affected neurons. In the prion diseases, such as 
Creutzfeldt-Jakob disease in humans, scrapie in sheep, the prion protein not only 
aggregates but also the aggregated protein is apparently infectious in the absence of 
genetic material. In amyotrophic lateral sclerosis (ALS, Lou Gehrig’s disease), 
mutations in superoxide dismutase lead to astrocytic inclusions in transgenic mice. 
 
Table1.1 
 
 
In AD, one finds in the cerebral cortex the extraneuronal plaques and 
intraneuronal tangles first described by Alois Alzheimer nearly a century ago. The 
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major protein component of the plaques is the amyloid-
β
 protein (A
β
), and the tangles 
are composed of filaments of the microtubule-associated protein tau (τ). The A
β
 is so 
named because of the 
β
-pleated sheet secondary structure of the amyloid protein, while 
τ proteins are critical for polymerization and stabilization of tubulin in axonal 
microtubules and the cross-linking of microtubules to other cellular structures.5 6 
These protein aggregates cause the degeneration of a specific subpopulation of 
neurons either because these aggregates are formed primarily in certain regions of the 
brain (i.e., where conditions are conducive to aggregate formations) or because certain 
neuronal subtypes are more sensitive to these toxic aggregates than other neurons 
leading to a slow but progressive increase of dementia.  
Whether plaques and tangles independently or jointly are the causative agents of 
neuronal degeneration or, instead, a marker of the disease is still an issue of some 
debate. Plaques and tangles may be present in other diseases and even normal aging, 7 
but AD does not develop in the absence of both. Plaques and tangles can occur 
independently of each other in diseases other than AD,8 9 10 11 12 13 but there is 
increasing evidence that A
β
 and τ are linked in AD 14 15 16 and there is some evidence 
that A
β
 might precede τ formation. 
The amyloid plaques and neurofibrillary tangles (Figure 3.1) of the AD brain have 
been subjected to rigorous pathological analysis at the cytological and biochemical 
levels, with the hope that further clues to disease etiology might be gleaned. In AD, 
dense deposits containing fibrillar forms of A
β
 are intimately associated with dystrophic 
(degenerating) axons and dendrites (together referred to as neurites),17 and these neuritic 
plaques are found in cerebral and midbrain regions associated with cognition and 
memory.18 19 20  
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Figure 3.1 
 
 
Neuritic plaques contain amorphous, nonfibrillary Aβ  and are found in areas of 
the brain generally not implicated in clinical AD. Moreover, the diffuse plaques are 
often found in abundance in elderly, cognitively normal people, leading to the 
suggestion that these diffuse plaques may be the precursors to pathogenic dense 
plaques. Neurofibrillary tangles are also found in the brain regions critical to higher 
brain function. Biochemical analysis reveals that the filamentous form of the τ protein 
found in these tangles is hyperphosphorylated. Tau hyperphosphorylation renders 
insoluble this otherwise highly soluble cytosolic protein, and this modified form of τ is 
also found in many plaque-associated dystrophic neurites. Interestingly, tau-containing 
neurofibrillary tangles occur in a number of other, uncommon neurodegenerative 
diseases. In contrast, the amyloid containing neuritic plaques are unique to AD. 
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The Cholinergic Hypothesis 
 
 
Another constant observation in post mortem AD brain is the loss of cholinergic 
markers such as acetylcholine (Ach) and choline acetyltransferase (ChAt).  
First established in 1976 the “cholinergic hypothesis” postulates that many of the 
cognitive, functional and behavioral symptoms derive from a deficiency in cholinergic 
neurotransmission, linked to the loss of cholinergic neurons in the nucleus basalis and 
other nuclei and that cause an inability to transmit nerve cell impulses across 
cholinergic synapses.21 22 The cholinergic hypothesis of AD evolved from original 
observations by Davies and Maloney in 1976, who first reported decreased numbers of 
cholinergic neurons in autopsy brain tissue from patients with AD.23 24  It was 
postulated that a deficiency of the neurotransmitter, ACh, in the brain and subsequent 
reduced neurotransmission at central cholinergic experienced by AD patients. 
 
Figure 4.1: Functional features of the cholinergic system. 
Ach= acethylcoline; Ache= acetylcholinesterase, BuChE= butyrylcholinesterase; 
ChAT= choline acethyltransferase; CoA= coenzyme A. 
 
 
 13 
 
 Because cholinergic function is required for short-term memory function, it was 
determined that cholinergic deficit in AD was also responsible for much of the short-
term memory deficit.25 Markers for cholinergic neurons such as choline 
acetyltransferase (ChAt) and acetylcholinestrase (AChE), which are enzymes 
responsible for synthesis and degradation of ACh, respectively, are decreased in the 
cortex and hippocampus, areas of the brain involved in cognition and memory. 26 In 
particular, the earliest loss of neurons occurs in the nucleus basalis and the entorhinal 
cortex, where cholinergic neurons are preferentially affected. As the illness progresses, 
up to 90 percent of cholinergic neurons in the nucleus basalis of Mynert may be lost. 26 
27 The resultant decrease in ACh-dependent neurotransmission is thought to lead to the 
functional deficits of AD, much as dopaminergic deficits underlie Parkinson's disease 
and its clinical manifestations.26  27 
To improve cholinergic neurotransmission, different strategies have been 
investigated including the increasing of acetylcholine synthesis, the augmentation of 
presynaptic acetylcholine release, the stimulation of cholinergic postsynaptic muscarinic 
and nicotinic receptors, and the reduction of acetylcholine synaptic degradation with 
cholinesterase inhibitors. Clinical drug trials in patients with AD have focused on drugs 
that augment levels of ACh in the brain to compensate for losses of cholinergic function 
in the brain. These drugs have included ACh precursors, muscarinic agonists, nicotinic 
agonists, and cholinesterase inhibitors (AChEIs).28 29The best developed and most 
successful approaches to date have used cholinesterase inhibition.30 31  
The first drug approved for general clinical use in AD was Tacrine (Cognex ®). 
However, three new cholinesterase inhibitors (AChEIs) are currently available: 
Donepezil (Aricept ®), Rivastigmine (Exelon ®), and Galantamine (Reminyl ®).32 33 
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All of these drugs have been tested primarily in patients with AD, with most trials 
studying treatment in patients with mild to moderately severe illness. Each of these 
compounds has its specific mode of action and inhibition constants (IC50) (Table 2.1), 
which does not completely abolish all the functions of AChE and include some non-
desirable side effects. Some of them present hepatotoxicity, nausea or vomiting, 
diarrhoea, abdominal pain, anorexia, weight loss, dizziness and bradycardia.  
The clinical trials using the three main marketed compounds, Donepezil, 
Rivastigmine and Galanthamine have shown that the first one appears to be effective, of 
simple use and the best tolerated. The other two compounds are of similar effectiveness 
but less well tolerated.  
Table 2.1 
Compound IC50 (nM) 
AChE 
IC50 (nM) 
BuChE 
BuChE: AChE 
ratio 
Donezepil 23±5 7420±390 322 
Rivastigmine 4150±160 37±5 0.009 
Tacrine 190±40 47±10 0.247 
Galanthamine 800±60 7300±830 9.125 
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 Tacrine (THA), a competitive inhibitor of AChE interacting at the active site of 
the enzyme, has a substantial lipid solubility concentrating itself in the brain. It interacts 
with muscarinic receptors and inhibits monoaminooxidases. Some studies have 
suggested that the improvement of cognitive function by THA is associated with an 
increase in the number of nicotinic binding sites or glucose metabolism among other 
effects.34 This reversible non-selective inhibitor causes cholinergic toxicity, due to its 
specificity towards butyrylcholinesterase (BuChE), another type of cholinesterase able 
to hydrolyse ACh among other ester compounds and that participates in the cholinergic 
regulation at human CNS. The use of Tacrine approved as the first AChE inhibitor by 
the U.S. Food and Drug Administration is limited because of its severe, though 
reversible, hepatotoxicity.  
Galanthamine (GAL) is a plant alkaloid which is known to diminish cognitive 
deficits in animal models of learning and memory. GAL directly inhibits AChE activity, 
showing a weaker activity on BuChE. However peripheral side effects have been 
suggested.35.  GAL stimulates preand post-synaptic nicotinic receptors acting as an 
allosteric modulator enhancing the production of ACh and other neurotransmitters,36 
although the clinical significance of this finding is not yet clearly understood.  
Donepezil interacts with the active site of the enzyme.37.  The piperidine 
derivative Donepezil, approved for clinical use in 1996, is a specific reversible inhibitor 
of AChE, which increases the concentration of Ach in the CNS for synaptic 
transmission. Donepezil seems to be selective towards the cerebral cortex38  and well 
tolerated. Mild transient adverse effects are observed and appear to be dose related. 
Rivastigmine, as well as Tacrine, inhibits both AChE and BuChE. It was 
approved for clinical treatment of AD on April 21, 2000.39 It forms a carbamoylated 
complex with the active-site serine 40
 16 
“pseudo-irreversible” inhibition. It is described as brain selective with particular activity 
in the cortex and hippocampus. The most common side effect seen in clinical trials is 
the one affecting the gastrointestinal tract. In these studies, the treatment with 
Rivastigmine proved to be economically beneficial only after two years of treatment 
because it finally delayed the progression of the disease, but did not stop it.  
Although most AChEIs tests how a positive effect over the cognitive loss seen in 
AD patients, the major differences seen in a variety of clinical studies can be explained 
on the basis of the different criteria used to evaluate the compounds (selection criteria of 
patients, age of subjects, severity of disease, concomitant illnesses and medications, 
variable instruments of assessment and side effect evaluation).41  These criteria depend 
on the severity and frequency of the side effects, as well as, on the percentage of 
responding patients and dropouts. Clinical studies have shown that ending the 
administration of the AChEIs in patients is related to a slow return towards the 
deterioration state, suggesting an additional unknown effect of the inhibitors. 41 42 
The newest drug for AD, Memantine (Namenda ®), breaks out of the ACh-
enhancing mode and focuses on a different receptor complex: the NMDA receptor. 
 
Figure 6.1 
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Glutamate is the main excitatory neurotransmitter in the CNS and has a role in 
neurotransmission and plasticity. Glutamate receptors are divided into NMDA, AMPA, 
and kainate subtypes. The NMDA receptor has a complex structure with several binding 
sites for NMDA and glutamate and a central ion channel capable of binding 
phencyclidine. NMDA-receptor activation generates a longlasting influx of Ca2+ into 
neurons, which is thought to be involved in long-term potentiation a cellular process 
that underlies learning and memory. 43 44 In pathogenesis, such as the neurodegeneration 
of AD, an increase of extracellular glutamate is thought to lead to excessive activation 
of NMDA receptors with consequent intracellular accumulation of Ca2+. This 
intracellular accumulation of calcium then initiates a cascade of events that results in 
further neuronal death.45 46 
Memantine (Namenda ®) is a non-competitive, moderate-affinity, phencyclidine-
site, NMDA antagonist that might protect neurons from glutamate-mediated 
excitotoxicity without preventing physiological activation of the NMDA receptor. It 
blocks the effects of abnormal glutamate activity hat may lead to neuronal cell death 
and cognitive dysfunction. 
 Memantine was approved for the US market in October 2003 and has been used 
in Europe for many years. It is a drug specially developed for use in moderate-to-severe 
dementia. It is not a AChEIs and therefore, is different from other drugs currently used 
for AD treatment. Several studies have been done to establish the consequence of the 
association between Memantine and other cholinesterase inhibitors. 
Farlow and colleagues 47 recently reported on preliminary results from a 6 month, 
multi-centre, randomised controlled trial of Memantine combined with Donepezil 
compared with Donepezil and placebo in 400 patients with moderate to severe AD. The 
Memantine–Donepezil combination therapy led to improvement from baseline and 
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significant benefit over the Donepezil–placebo combination. Additional data are needed 
on Memantine as monotherapy, in combination therapy in mild-to-moderate AD, and in 
early stage dementia when it might, on the basis of its neuropharmacological properties, 
be most effective. 
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The Amyloid Hypothesis 
 
The common theme of Aβ  production and deposition has bolstered the “amyloid 
hypothesis” of AD pathogenesis , which states that production and deposition of Aβ  in 
the form of fibrils leads to neuronal cell death and eventually to the clinical presentation 
and progression of AD.48  
Amyloid plaques are deposits composed primarily of β-amyloid insoluble 
peptides of approximately 4 kDa generated from the precursor Amyloid Precursor 
Protein (APP), a type Ia transmembrane protein, characterized by a large NH2-terminal 
extracellular/cytosolic domain and a small intracellular/luminal COOH-terminal domain 
and expressed in neurons and glia where it is synthesized and contranslationally inserted 
into the endoplasmatic reticulum (ER).49 
The APP is enzymatically cleaved by three different forms of proteases (enzymes 
that break down protein molecules) named α-, β-, and γ-secretase. 50  These proteases 
are a heterogeneous group located in various cellular regions. The order in which these 
proteases cleave APP determines whether Aβ  is formed. 51 52 For example, cleavage of 
APP by α-secretase produces fragments that are substrates for γ-secretase, but 
processing of these fragments by γ-secretase does not lead to Aβ . 53 54 In contrast, 
cleavage of APP by β -secretase produces a peptide fragment that is a substrate for γ-
secretase that is converted by γ-secretase to Aβ  40 or Aβ  42.55  There is likely to be an 
additional step that determines which form of Aβ  is produced. 56 
Two distinct paths carry out the proteolysis of APP. Both appear to be regulated 
by numerous factors including stimulation of acetylcholine, serotonine, glutamate and 
neuropeptide receptor.57 58 
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Figure 7.1: The APP processing 
 
 
 
The dominant nonamyloidogenic α-pathway involving the α-secretase 
(metalloproteases such as the tumor necrosis alpha converting enzyme TACE and 
Adam10);  and represents the most important APP proteolysis (90%). APP is cleaved 
between Lys16 and Leu 17 of the A
β
 domain in the extracellular space and produce a 
soluble APPα fragment (sAPPα) and the αC- terminal fragment (α CTF) composed by 
88 aa and subsequently cleaved by γ-secretase to produce fragment p3 (3-kDa molecular 
weight). The sAPPα fragment was reported to have neurotrophic and neuroprotective 
properties against glucose deprivation and glutamate toxicity. Besides it stimulates 
neurite outgrowth and regulates synaptogenesis. 59 60 When APP undergoes non-
amyloidogenic processing, there is no release of intact 
β
-amyloid peptide, and the 
generated stubs do not aggregate and do not have amyloidogenic activity. 
The second amyloidogenic 
β
-pathway employs 
β
-secretase (BACE1 or 
β
-site APP 
Cleaving Enzyme 1) which is largely present in the distal Golgi membrane.61 β-
secretase is responsible for cleaving APP at the N-terminus of A
β
 between Asp 1 and 
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Met-1. Thus the generated soluble APPβ  fragment (sAPPβ ) leaves the scene, whereas 
the membrane-bound β  fragment (β  CTF) is in turn cleaved by γ-secretase to produce 
Aβ  of 40 or 42 aa length. The γ-secretase cleavage of β  CTF leaves an unstable CTFγ 
composed by 57-59 aa residues. 62 Both Aβ -40 and Aβ -42 are produced in normal 
individuals but in proportions of 9:1 .The longer and more hydrophobic Aβ -42 is much 
more prone to fibril formation than is Aβ -40 and even though Aβ -42 is a minor form of 
Aβ  it is the major species found in cerebral plaques.  
AD causing mutations in APP near the γ and β -secretase cleavage sites, alters the 
way in which APP is processed in favour of increasing the ratio of amyliodigenic Aβ -42 
fragment that has a greater propensity to self aggregate and may provide a nidus for 
extracellular amyloid deposition.  
(The identification of the biological mechanism that cause the formation of 
amyloid plaques and neurofibrillary tangles typical of AD and the identification o the 
amyloid-β  precursor protein (APP) as the main precursor of these plaques, lead 
scientific research to focus its attention on the two strong therapeutic targets γ -and β  -
secretases that are directly responsible of the Aβ  peptide generation.)  
The pharmacological inhibition of these enzymes could provide a targeted therapy 
for amyloidopathy in AD and in particular β -secretase that catalyses the first step of Aβ  
production is thought to be an ideal therapeutic target. 
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γ
-Secretase 
 γ
-Secretase is a high molecular weight multimeric protein complex that carries out 
its proteolytic function within the membrane. How exactly the substrate is hydrolyzed 
within the membranous environment is uncertain since it requires the presence of a 
water molecule bound to the enzyme in this hydrophobic environment, it represents an 
unusual transformation. 
After either β  or α-secretase release the APP ectodomain, the resulting C83 and 
C99 nAPP C-terminal fragments are clipped in the middle of their transmembrane 
regions by this enzyme.63  Normally, about 90% of the proteolysis occurs between Val 
40 and Ile 41 (Aβ  numbering) to give Aβ40; roughly 10% takes place between Ala 42 
and Thr 43 to produce Aβ42. Minor proportions of other C-terminal variants, such as 
Aβ39 and Aβ43, are formed as well. For this reason 
γ
-secretase is central to AD 
pathogenesis, because of its importance in determining the ratio of Aβ40 to Aβ42 , but 
the exact mechanism of its action remains elusive.  
It has been hypothesised that 
γ
-secretase is a multiprotein complex and some 
studies suggest that presenilin proteins are the catalytic site of this complex and in 
particulary presenilin-1 (PS-1). 64 
However, it is unclear whether PS-1 is 
γ
-secretase, or whether PS-1 is not 
γ
-
secretase but instead interacts with the enzyme to release Aβ . In either case PS-1 is 
essential to 
γ
-secretase activity, and inhibition of PS-1 function is a potential strategy 
for developing Alzheimer’s disease therapies. 
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γ
-Secretase inhibitors 
The development of γ-secretase inhibitors began providing information about the 
characteristics of this mysterious protease and considering that γ-secretase does not have 
a specific aminoacid sequence requirement for substrate recognition but rather has a 
loosely defined preference for hydrophobic amino acid sequences.  
Taking into account of this many γ-secretase inhibitors have been reported. Most 
of this development occurred in the absence of any knowledge of the nature of the 
enzyme complex since the key discoveries were made only more recently. Following 
the initially reported peptidic compounds similar to many “traditional” aspartyl protease 
inhibitors, more recent efforts have allowed the identification of a range of structurally 
diverse, nonpeptidic inhibitors which often attain high levels of potency in cell-based 
assays of inhibition of γ-secretase cleavage.  
The first reported inhibitors were short, hydrophobic peptide aldehydes originally 
designed as calpain inhibitors (1.1-3.1, Figure 8.1), and these compounds blocked Aβ  
production at the γ-secretase level in APP-transfected cells with IC50s of 5-200 
M.65 66 
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Peptide aldehydes are in fact able to inhibit serine-cysteine and aspartyl acid 
proteases. At low concentrations, peptide aldehydes are reported to increase Aβ  
production and at higher concentrations to inhibit proteases.67 Authors explain this 
property by the inhibition, at low concentrations, of proteosomal degradation of α and β  
secretase-cleaved APP making more substrate available for γ secretase cleavage, al 
higher concentrations Aβ  secretion would be explained by blocking cysteine protease 
having roles in protein processing and trafficking in the secretory pathway.68 
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Initially known to act on calapin, MG132 compound 1.4 in Figure 8.1 was the 
most potent peptide aldheyde prototype with IC 50 of about 5 M against Aβ -40 and 25-
50  M against  Aβ -42 in a cell based assay. Another calpain inhibitor MDL 28170  in 
Figure 8 inspired the syntesis of a series of different aldehyde derivatives.  
Further optimization of these inhibitors has been carried out by the Scios group 
utilizing combinatorial chemistry to provide analogs such as 6.1 in Figure 10.1 (IC50 
9.6 M – N9 cells).69 Questions remain however as to the applicability of reactive 
functional groups such as these aldehydes to therapeutically relevant molecules, owing 
to their instability and potential for generating toxicity. 
 
Figure 10.1 
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The utility of potential transition state isosteres has been extended by the Merck 
group with the identification of the dipeptide, hydroxyethylene isostere 7.1 in Figure 
10.1. 70 71 In contrast to previous compounds, this inhibitor showed potent inhibition of 
Aβ

 generation in a range of cell lines with Aβ40 IC50 values in the range 48-402 nM 
with similar levels of potency for inhibition of Aβ42 production. A series of 
structurally-related statine derivatives (e.g. 9.1 in Figure 11.1) have been disclosed by 
Bristol Myers Squibb.72 73 
More recently this area has been revisited with the disclosure of isosteres such as 
8.1 74  in Figure 11.1 and related hydroxyamides 75 and succinates. 76 
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Figure 11.1 
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The use of semi-peptidic inhibitors has also been extensively exploited in a range 
of disclosures from the Elan/Lilly group.77 78 Initial reports detailed 3,5-
difluorophenylacetate- capped dipeptide esters including 10.1 in Figure12.1 (AN- 
37124, DAPT) which is a potent γ-secretase inhibitor in vitro and has also demonstrated 
robust efficacy in vivo.79 Modification of these early compounds resulted in 
benzodiazepine-containing analogs such as 11.1 (Figure 12.1). 80  
Further elaboration, taking advantage of the increased activity observed with 
several metabolites bearing an additional benzylic hydroxyl group, led to the discovery 
of mandelate analogs such as  12.1 and  13.1 in Figure 12.1(LY- 411575) which have 
shown high levels of potency in whole cell assays (e.g 13.1 in Figure 12.1; IC50 
119pM).81 
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Figure 12.1 
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In contrast to the previously described amide-containing inhibitors, more recent 
disclosures have shown the utility of lipophilic motifs based around a sulfonamide 
moiety. The Amgen group has utilized fenchylamine sulfonamides as moderately potent 
inhibitors. Sulfonamides (e.g. 14.1 in Figure 13.1) prepared from amino alcohols have 
also been claimed by the Wyeth/Arqule groups.82 83 An alternative series of diaryl 
sulfonamides exemplified by  15.1 and  16.1 in Figure 13.1 (IC50 7-13nM solubilized 
enzyme assay 84) has also been disclosed by the BMS group. 85 
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Figure 13.1 
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In a series of closely related disclosures, the Schering group have utilized a 
variety of sulfonamides, for example piperidine 17.1, 86 tetrahydroquinoline 18.1 (IC50 
30-535nM in DKF167 cells expressing C99),87 and 2, 6-disubstituted piperidine 19.1 
(IC50 0.2nM).
88  
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β
-Secretase 
 β
-Secretase-1 (BACE1) is a 501 residue transmembrane aspartyl protease also 
known as Asp2 (for novel aspartyl protease 2) 89 90 and memapsin2 (for membrane 
aspartyl protease / pepsin 2),91 closely related to the pepsin protein family. It is 
characterized by a large extracellular domain, where two aspartyl residues involved in 
β
-secretase activity reside  and by a short intracellular domain containing a sorting 
sequence that was shown to be involved in the trafficking of the protein. 
Since BACE1 co-localizes to endosomes and requires an acidic pH for its activity 
it is supposed that the endosomes are the cellular compartment where BACE1 is mostly 
active. Interestingly, endosomal dysfunction has been linked to Alzheimer's disease and 
neurodegeneration, and it was previously reported that 
β
-secretase cleavage of APP 
occurs upon internalization. It cannot be excluded that BACE1 is active also in 
intracellular compartment distinct from the endosomes; in fact, BACE1 recycles from 
the endosomes to the trans-Golgi network and localizes and is active within the lipid 
rafts, invaginations of the membrane rich in cholesterol and other lipids 92  in proximity 
of membrane structures. 
Soon after the discovery of BACE1, searches identified a homologous novel 
aspartyl protease, BACE2 (also termed Asp1, mempapsin1, and DRAP).89 91 93 94 
BACE2, which is expressed in highly vascularized tissues such as heart, kidney, 
and placenta has been identified on chromosome 21 95 and share 64% amino acid 
similarity with BACE1. Cell transfection studies demonstrate that BACE2 cuts APP at 
the 
β
-secretase site. 96 97 98 
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However, BACE2 cleaves with higher efficiency at two other positions within the 
A
β
 domain near the α-secretase cleavage site. Thus, BACE2 may play a role in the 
pathogenesis of familial forms of AD (FAD). However, BACE2 usually functions like 
an alternative α-secretases so that the processing of wild-type APP by BACE2 
diminishes A
β
 production in cells. 
 
Bace  inhibitors 
 
Since it has been established that γ-secretase cleaves various substrates, some of 
which might have important physiological roles (Notch cleavage), γ-secretase inhibitors 
might have insurmountable mechanism-based toxicity.99 
Taking into account this observation developing 
β
-secretase inhibitors appears to 
be more encouraging. In fact BACE1 appears to have a single substrate APP, and 
inhibiting BACE1, and therefore preventing the abnormal generation of the A
β
 

peptides 
represents a rational biochemical approach to preventing disease progression in AD. 
Accordingly, BACE1 might be considered the primary target for lowering A
β
. 
 
Transition-state analog inhibitors 
 
Few inhibitors have been described and the majority of compounds designed are 
transition state analogues derived from the amino acid sequence around the cleavage 
site of APP. They represent a peptidomimetic BACE inhibitors substrate-based and 
were designed using the knowledge of the specificity and kinetics of BACE1 and they 
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can be divided in statine isosteres (Figure 15.1) and hydroxyethylene isosteres (Figure 
16.1). 
 
Figure 15.1: Statine isostere. Hydrogen bonding pattern based on Piana and 
Carloni 100 and Northrup 101 
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Figure 16.1: Hydroxyethylene isostere 
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The first compound synthesized was based on 
 
 two residues of the Swedish mutant 
APP, replacing the aminoacid Leucine with Statine. This peptide analogue inhibited 
β
-
secretase activity, albeit poorly, with an IC50 of 40 M in solubilized extracts of human 
brain membranes. Modifications of the statine hydroxyl or replacement of S- with the R-
statine diastereomer led to loss of inhibitory activity, indicating that, as in other statine-
containing inhibitors of aspartyl proteases, inhibitory potency is dependent on an 
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unmodified hydroxyl residue in the appropriate configuration. However, replacement of 
the Asp with the aminoacid valine resulted in a substantial increase in potency (IC50~30 
nM), providing a suitable reagent (20.1, Figure 17.1) for affinity purification of β -
secretase.  
 
Figure 17.1 
 
H2N-Lys-Thr-Glu-Glu-Ile-Ser-Glu-Val-Asn-NH
OH O
Val-Ala-Glu-Phe-OH
20.1  
 
Not surprisingly though, given its size and the presence of hydrophilic residues, 
this compound displays no inhibition of Aβ  production in whole cells. 
 In order to reduce the molecular weight of inhibitors, Tang and colleagues at the 
University of Oklahoma in collaboration with Ghosh and co-workers have reported the 
development of peptidic BACE inhibitor OM99-2 in Figure 18.1 which has a BACE 
IC50 of 0.002 M.
102 This compound, an octapeptide based on the cleavage site of 
Swedish mutant APP, represents the main hydroxyethylene dipeptide isostere in which 
registration of the amino acid side-chains exactly mimics a peptide substrate. 
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Figure 18.1 
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Figure 19.1: Peptidic hydroxyethylene BACE inhibitor OM 99-2 and its binding mode 
in BACE (Brookhaven entry 1FKN) 
 
 
 
 
They have further reported on using X-ray structure-based modification of the 
lead OM99-2 that led to the discovery of a series of potent and considerably low 
molecular weight peptidomimetic BACE inhibitors such as 22.1 (Figure 20.1). 
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Figure 20.1 
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The Elan/Pharmacia team has reported  the development of other cell-permeable 
BACE inhibitors. Replacement of the Leucine residue with a noncleavable Statine (sta) 
residue and replacement of the  Asp with the Valine residue resulted in analogue 23.1 
(IC50 = 0.03  M; Figure 21.1). Further truncation of the N-terminus and C-terminus 
resulted in the identification of the smaller peptidic inhibitor  24.1 (IC50 = 0.3  M; 
Figure 21.1).103 
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Figure 21.1 
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Further modification of the central core region and combination of the optimal N- 
and C-terminal mimetics resulted in a potent but cell-permeable BACE inhibitor 26.1 
(IC50=0.12  M; EC50=4  M; Figure 21.1).
104 The corresponding diacid 25.1 (Figure 
21.1) was a potent inhibitor of the enzyme (IC50=0.02  M) but had no inhibition of Aβ  
in human embroyonic kidney cells presumably because of poor cellular permeability. 
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Further work in both the statine and hydroxyethylene series has been directed toward 
optimizing the early lead inhibitors to improve pharmaceutical properties, focusing first 
on increasing cell penetration by reducing molecular weight. 
Researchers at Pfizer have prepared an inhibitor using a unique hydroxyethylene 
isostere with a cyclohexylmethyl group instead of leucine and a dimethyl carbinol 
substituent instead of Asp.105Compound 27.1 in Figure 22.1 has a BACE1 IC50 = 49 nM 
as determined by ELISA. 
In efforts to increase solubility, a series of inhibitors of structure 28.1 (Figure 
22.1) with a C-terminal pyridylmethyl group was prepared  and more recently Takeda 
has published an application describing compounds utilizing an oxidized 
hydroxyethylamine isostere-type template.106 A variety of benzylic amines are utilized 
on the prime side as indicated in structure 29.1 in Figure 22.1. 
 A number of these compounds are reported to have IC50s < 1  M against the 
enzyme and activity in a cellular assay of Aβ  lowering. 
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Figure 22.1 
 
 
 
Additional isosteres claimed as BACE inhibitors include reduced amides such as 
30.1 (Figure 23.1) in which the carbonyl of the scissile amide has been removed.107 
Another recent application claims a variation with an amino binding element similar to 
the compounds described by Sunesis, but with an ether-linked prime side binding group 
as in amine 31.1 in Figure 23.1.108 
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Figure 23.1 
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Non transition-state analog inhibitors 
 
In addition to compounds containing transition state mimics as well as peptide and 
amino acid derived structures, several carbocyclic and heterocyclic BACE inhibitors 
have been disclosed. In general these compounds do not contain an obvious transition 
state mimic.  
Takeda for example just recently described a non-peptidic class of BACE 
inhibitors, most probably identified from a screening approach. The tetraline derivatives  
discovered have a trisubstituted long chain-amines with more than 1 aromatic ring in the 
chain. In particular the substituted tetralin compound 32.1 in Figure 24.1was reported to 
have a BACE1  IC50 = 250 nM. 
 
Figure 24.1 
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The ability of piperidine derivatives to function as inhibitors of the aspartyl 
protease renin was first discovered by the Roche group through a high throughput 
screening effort.109 110 111 112 X-ray crystal structure data for piperidine inhibitors 
complexed to renin showed that the protonated piperidine nitrogen was positioned 
between the two catalytic aspartyl acid residues (Figure 25.1). 
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Figure 25.1: Piperidine inhibitors 
O
O H O
O
HH
N
P2'
+
 
 
Interestingly, binding of the piperidines required conformational changes within 
the renin active site relative to binding of peptide-derived peptidomimetic inhibitors. It 
has therefore been proposed that the piperidines stabilize an alternate conformation of 
renin.113 Incorporation of the piperidine scaffold into BACE inhibitors has been 
disclosed in patent applications by several groups.  
Piperidines were included in a Vertex patent that focused on inhibitors having 
required distances between key hydrogen bonding functionalities.114 Compound 33.1 in 
Figure 26.1 was indicated to be amongst the more potent BACE inhibitors, having a Ki 
≤ 3  M. Patent applications have appeared from Elan that encompass piperidine and 
other cyclic amine BACE inhibitors.115 116 
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Figure 26.1 
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Ester 34.1 in Figure 27.1 is one illustrated example with modest BACE inhibitory 
potency (IC50=11  M). More recently, two patent applications have appeared from 
Actelion covering 3- or 4-aminomethyl piperidines 117 and 3- or 4-aminopiperidines.118 
Aminomethyl piperidine 35.1 (Figure 27.1), which is described as having an IC50 ≤ 3 
 M, is a representative of the Actelion chemotype. 
 Researchers at De Novo have described a similar series of piperazine inhibitors 
exemplified by compound  36.1, which also has an IC50 = 3 µM.
119 
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Figure 27.1 
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Chapter 2 
 
 44 
 
Aim of the thesis 
 
The studies of this Ph.D thesis, carried out in collaboration with Siena Biotech 
S.p.A, involve the identification and the design of novel small molecules with the 
potential of modulating Alzheimer’s Disease (AD). The pathology is a progressive, 
neurodegenerative disease characterized by behavioural disturbance and a general 
decline in cognitive function. Current therapies rely on the use of cholinesterase 
inhibitors which temporarily improve cognitive function but do little to address the 
progression of AD.120  
Many therapeutic strategies to this end have been proposed, including the 
suppression of amyloid-
β
 peptide (A
β
) formation by inhibition of the proteases that 
cleave Amyloid-
β
 Precursor Protein (APP).121 
The more aggregable, less-soluble A
β
 (1-42) is the main component of the 
amyloid plaques found in diseased brain tissue, despite comprising only about 10% of 
total secreted A
β
, and hence compounds selective for the inhibition of A
β
 (1-42) 
production may be of particular interest. Consequently, since the discovery of 
β
-
secretase (BACE), the aspartyl protease responsible for the initial cleavage of APP, 
intensive efforts have focused on the synthesis of the new enzyme inhibitors.  
The identification of non peptidomimetic BACE inhibitors has proven to be a 
challenging undertaking. To augment the disclosure of peptide-derived BACE 
inhibitors, a few companies have published non peptidomimetic BACE inhibitors and 
the knowledges to date are few and limited to published patent applications.  
Companies like Elan and Actelion disclosed several series of compounds that 
posses good BACE inhibitor proprieties with associated values of IC50 in the 
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micromolar range (compounds 1.2, 2.2 in Figure 1.2). These compounds spanned 
multiple classes of heterocyclic templates such as piperidines. 122 123 124 Moreover, 
Takeda disclosed a new series of aminoethyl-substituted tetralins (compound 3.2 in 
Figure 2.1) as BACE inhibitors. 125  
 
Figure 1.2 
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Based on these new compounds, the aim of this PhD Thesis was to identify new 
BACE inhibitors that possess appropriate properties for drug development, such as good 
potency, small size, and high selectivity.  
The present work can be divided in four parts : 
•  Synthesis of patented compounds  
The two patented derivatives 1.2 and 3.2  in Figure 1.2 were synthesized  and then taken 
as model compounds for the next studies. 
• 4-aminopiperidine derivatives 
A series of new piperidine derivatives of a generic structure X in Figure 2.2 were 
designed and synthesized. These new compounds are characterized by the presence of a 
4-aminopiperidine scaffold and they are a form of hybrid of the two known reference 
compounds 1.2 and 2.2 in Figure 1.2. 
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Figure 2.2: New 4-piperidine derivatives of generic structure  X 
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These molecules are characterized by the presence of an aromatic amido or 
sulphonamido moiety in which the two groups R1 and R2 can be simultaneously or 
alternately aryl halides or biphenylic groups. The N atom of the piperidine ring has also 
been substituted with Boc.  
• Tetraline derivatives 
Based on the patent reported from Takeda company in which an aminoethyl-substituted 
tetraline as a BACE inhibitor is shown, in the third part of this study we synthesized 
other non peptidomimetic derivatives using the compound 3.2 in Figure 3.2 as a starting 
point.  
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Figure 3.2: New derivatives E, F1 and F2 
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In particular poly-aromatic substituted compounds (E, F1 and  F2 in Figure 3.2) 
have been designed and synthesized by replacing the central tetralinic moiety of 
patented compound with an indane cycle and with a isoprenoid moiety. 
• Carbazole derivatives 
 From a screening performed at Sienabiotech a series of commercially available 
carbazole derivatives (compounds 4.2, 5.2 and 6.2 in Figure 4.2) were discovered to 
have a significant inhibitory activity on BACE.  
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Figure 4.2 
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Inspired by screened compound 4.2 and 5.2 we have accomplished the synthesis of a 
new series of compounds by designing a generic structure Y in Figure 5.2 where 
modifications have been brought both on the carbazole and on the sulphonamido 
moieties and various substituents were introduced on the aryl R1 and R2 groups. 
 
Figure 5.2: New carbazole derivatives  of generic structure Y 
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Taking compound 6.2 as a reference, we therefore accomplished the synthesis of  
derivatives L and M showed in Figure 6.2 in which the carbazole moiety is 
unsubstituted (compound L) or di-chloro substituted ( compound M) and derivatives N-
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P in which the carbazole moiety has been replaced with indole moieties, maintaining the 
naphtylamino moiety as the common portion. 
Figure 6.2: New carbazole derivatives L-P 
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Furthermore all the synthesized compounds have been tested with a time resolved 
fluorescence quenching assay at Siena Biotech laboratories in order to evaluate their 
inhibitor activity on BACE. 
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Synthesis of Patented Compounds 
 
 
In a first stage of this project we accomplished the synthesis of compounds 1.2 
and 3.2 (Figure 7.2) that represent two model compounds for  the next studies. 
 
Figure 7.2: Patented compouds 
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 For compound 1.2 we did not apply the conventional strategy described in the 
patent but a different synthetic procedure planned in our research laboratory using 
appropriate methods  also known in literature. 126 127 128 129 The original patent in fact 
described a well-constructed synthesis which would have involved many steps showing 
disadvantages in term of yields. Moreover, it would have started from a non 
commercially available compound Z (Scheme 1.2) which would have to be synthesised 
from appropriate precursors without clear literature references reported in the patent.  
 
Scheme 1.2 Original synthesis of compound 1.2 
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The synthesis of compound 1.2 was then performed as shown in Scheme 2.2. 
 
Scheme 2.2: Synthesis of compound 1.2 
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Compound 1.2 was prepared in a racemic trans form in five steps starting from 
the commercial available N-benzyl-piperidone 7.2 that was treated with PhMgBr in a 
Grignard reaction 126 to obtain the alcohol 8.2. This compound was subsequently treated 
with sulphuric acid and glacial acetic acid to obtain the resulting product of dehydration 
9.2. Hydroboration-oxidation reaction of 9.2 in the presence of BH3-sulfide-complex 
and H2O2 
127 yield the desired alcohol 10.2 that was obtained in good yield.  Compound 
10.2 was then submitted to reaction with biphenyl carbonyl chloride128 in the presence 
of triethylamine as the base and dimethylamino piperidine as the catalyst to yield the 
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ester 11.2. Finally, catalytic hydrogenation 129 reaction of compound 11.2 removed the 
benzylic group to yield the desired unprotected compound 1.2. 
The use of the synthetic procedure described above allowed us to obtain the 
desired compound 1.2 with a better yield with respect to that indicated in the patent.   
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Synthesis of compound 3.2 followed the procedure described in the original patent 
with the exception of the early on two steps in which we applied different synthetic 
procedures appropriately modified in our laboratory.130 The synthesis of compound 3.2 
is shown in Scheme 3.2. 
 
Scheme 3.2: Synthesis of compound 3.2 
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Compound 3.2 was prepared in a racemic form starting from the commercial 
available tetralone 12.2 according to the Marshall’s work.130 Compound  was initially 
treated with glyoxylic acid in the presence of NaOH and dry EtOH. The reaction was 
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left stirring under reflux to obtain the desired product 13.2. After Clemmensen reaction 
132 of 13.2 with zinc amalgam we obtained the desired reduction product 14.2. The 
synthesis proceeded according to the patent scheme and compound 14.2 was therefore 
treated with HBr 48% followed by reaction with SOCl2 and MeOH to get the desired 
unprotected alcohol 15.2.  
Compound 15.2 was subsequently treated with 4-phenylbenzyl chloride in the 
presence of NaH 60% to yield the product of condensation 16.2 that was submitted to a 
reduction reaction with LiAlH4 to obtain the alcohol 17.2. After reaction of 17.2 with I2 
in the presence of triphenylphosphine and imidazole the resulting iodine product 18.2 
was treated with piperidine and K2CO3 as base to get the desired tetraline derivative 3.2 
with 72% of yield.   
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4-aminopiperidine derivatives 
 
 The PhD work was focused on the analysis of the patented compounds 1.2 and 
2.2 showed in Figure 8.2 that represent two considerable examples of heterocyclic 
BACE inhibitors. 
Figure 8.2 
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In order to explore the possible structural analogies between compounds 1.2 and 
2.2 in Figure 8.2 a theoretical study was performed in Siena Biotech laboratories. To 
this scope Accelrys DS Pro software was used and compound alignment was carried 
out. Putative common features were first tethered and a flexible overlay carried out. 
Subsequently the molecules were minimised prior to a second rigid overlay to give the 
alignment hypothesis shown in Figure 9.2. 
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Figure 9.2: Comparison of the Actelion (green) and Elan (grey) molecules. Heteroatoms are 
coloured by atom type (N blue, O red). 
 
 
 
 
 
 
 
 
 
 
 
The resulting 3D molecular model obtained from the program allowed us to 
analyse in detail the spatial conformation of the two references compounds and their 
structural analogies. From the spatial superimposition of the two compounds we can 
observe that i)   the two piperidine rings are aligned; ii) the two biphenylic groups of 
compounds 1.2 and 2.2 are perfectly superimposable in spite of the fact that  they are in 
different positions inside the original molecules; iii) the phenylic ring of Elan patent 
(compound 1.2) resulted aligned to the benzoyl one of the Actelion (compound 2.2) 
albeit in the first one this scaffold is directly linked to the piperidine ring and in the 
second one is sensitively far away.  
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Looking at the Elan and Actelion structures we planned the synthesis of new 
piperidine derivates A, B, C, D, showed in Figure 10.2: new compounds are 
characterized by the presence of a 4-aminopiperidine scaffold and they are a form of 
hybrid of the two known reference compounds 1.2 and 2.2 in Figure 10.2. 
 
Figure 10.2: 4-aminopiperidine derivatives  
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Compounds A are characterized by the presence of a phenyl group directly linked 
to the N atom in position 4 of the piperidine ring. They have a benzensulphonamido 
scaffold that can be variously substituted with R1 groups as shown in Figure 10.2.  
Compounds B are derivatives related to the previous 4-aminopiperidine 
compounds, since they contain a phenyl group directly linked to the N atom in position 
4 of the ring and the sulphonamido group is replaced by an arylamidic moiety. 
Compounds C and D are 4-aminopiperidine derivatives that differ from the 
previous A and B compounds by the presence of a benzylamine scaffold variously 
substituted with R2 groups linked to the N atom in position 4 of the piperidine scaffold. 
In particular compounds C are benzensulphonamido derivatives and compounds D are 
arylamidic derivatives. 
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Compounds A1-A3 were synthesized with new synthetic methodologies learned 
during a work experience in Siena Biotech laboratories; reagents supported on solid 
phase were used and new parallel procedures both for their preparation and purification 
were introduced. The synthetic procedure applied for compounds A is showed in 
scheme 4.2. 
 
Scheme 4.2: Synthesis of compounds A1, A2, A3 
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 The commercial available N-boc-substituted piperidone 19.2 was dissolved in 
CH2Cl2 and treated with aniline in the presence of sodium cyanoborohydride and acetic 
acid. The reaction mixture was left under stirring for 3h at room temperature and then a 
solution of K2CO3 1M was added and the reaction extracted to obtain the desired 
secondary amine 20.2 in good yield.  Product 20.2 was then dissolved in CH2Cl2 and 
treated with the various sulphonyl chlorides. A catalytic amount of DMAP was added in 
each reaction mixture and a solid phase-supported amine (PS-DIEA) was used to 
capture HCl released in the reaction mixtures. Condensation reaction of product 20.2 
required too much time and afforded only small amounts of desired sulphonamide 
products. Purifications of these derivatives moreover was cumbersome because of their 
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trend to decompose. Only the three compounds A1, A2 and A3  showed in Table 1.2 
were obtained after chromatography purification in poor yields. 
Sulphonamides A1, A2 and A3 were therefore submitted to reaction with 
trifluoroacetic acid in CH2Cl2 in order to remove the Boc protecting group as showed in 
Scheme 5.2 but also in this case the reactions did not afford the hoped results probably 
on account of the instability of these compounds. 
 
Scheme 5.2: Synthesis of N-unprotected derivatives 
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Compounds B1-B5 were prepared by the same synthetic methodologies used for 
the previous compounds A as showed in Scheme 6.2. 
 
Scheme 6.2. Synthesis of compounds B1-B5 
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B1 R=Boc, R1= H
B2 R=Boc, R1=p-Me
B3 R=Boc, R1=p-Cl
B4 R=Boc, R1=3,4 Cl
B5 R=Boc, R1=p-OMe
 
The commercial available N-boc-substituted piperidone 19.2 was treated with 
aniline in the presence of  sodium cyanoborohydride and acetic acid and the resulted 
secondary amine 20.2 was treated with various acyl chlorides. Also in this case a 
catalytic amount of DMAP was added in each reaction mixture and a solid phase-
supported amine (PS-DIEA) was used to capture HCl released in the reaction mixtures. 
The resulting amides B1-B5 were therefore obtained in good yields after 
chromatography purification with silica and ionic exchange pre-packed cartridges. 
Compounds B1-B5 were then submitted to reaction with trifluoroacetic acid in 
CH2Cl2 in order to remove the Boc protecting group as showed in Scheme 7.2 but also 
in this case reactions did not afford the unprotected amides because of their instability. 
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Scheme 7.2: Synthesis of N-unprotected derivatives 
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Sulphonamido derivatives C1-C14 have been prepared with parallel synthesis 
following the general procedure showed in Scheme 8.2. 
 
Scheme 8.2: Synthesis of  compounds C1-C14 
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C6 R1=p-Ph, R2=H
C7 R1=H, R2=p-Ph
C8 R1=3,4Cl, R2=p-Ph
C9 R1=p-F, R2=p-Ph
C10 R1=p-Ph, R2=p-Ph
C11 R1=H, R2=m-Ph
C12 R1= p-Ph, R2=m-Br
C13 R1=H, R2=o-Ph
C14 R1=p-Ph, R2=o-Br 
 
The commercial available N-substituted piperidone 19.2 was treated with assorted 
benzylamines in the presence of sodium cyanoborohydride and acetic acid to obtain the 
desired secondary amines 21.2a and 21.2b in good yield.  
Compounds 21.2a and 21.2b were then dissolved in CH2Cl2 and subsequently the 
various sulfonyl-chlorides and catalytic amount of DMAP were added using a solid 
phase-supported amine (PS-DIEA) to capture HCl released in the reaction mixture. 
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Preparation of compound  C11 and  C13 on the contrary required a different 
synthetic procedure showed in Scheme 9.2. Compound 21.2c and 21.2d in fact were 
treated with phenylboronic acid in a cross coupling reaction in the presence of 
Pd(PPh3)4 to yield the secondary amine 21.2e and 21.2f that were therefore treated with 
benzensulphonyl chloride and catalytic amounts of DMAP and PS-DIEA to produce the 
desired compounds  C13 and  C11 in good yield. 
 
Scheme 9.2: Synthesis of compounds  C11 and  C13 
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The piperidine derivatives C1-C14 were also submitted to a catalytic 
hydrogenation with Pd/C to yield the related unprotected compounds as showed on 
scheme 10.2. 
 
Scheme 10.2: Synthesis of N-unprotected derivatives 
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Only the two unprotected derivatives  C15 and  C16 in Table 4.2 were obtained 
and then purified. 
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Aryl amidic compounds D are the related aryl amidic derivatives of previous 
compounds C. They have been prepared with parallel synthesis in the same manner 
following the general procedure  as shown in Scheme 11.2. 
 
Scheme 11.2: Synthesis of compounds D1-D19 
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D5 R1=3,4Cl, R2=H
D6 R1=p-Ph, R2=H
D7 R1=H, R2=p-Cl
D8 R1=p-Cl, R2=p-Cl
D9 R1=p-Me, R2=p-Cl
D10 R1=p-OMe, R2=p-Cl
D11 R1=3,4 Cl, R2=p-Cl
D12 R1=H , R2=p-Ph
D13 R1=3,4 Cl, R2=p-Ph
D14 R1=p-F, R2=p-Ph
D15 R1=p-Ph, R2=p-Ph
D17 R1=p-Ph, R2=m-Br
D19 R1=p-Ph, R2= o-Br
 
 
Compounds 21.2a and 21.2b obtained from reaction of the commercial available 
N-substituted piperidone 19.2 with assorted benzylamines in the presence of sodium 
cyanoborohydride and acetic acid were then dissolved in CH2Cl2 and subsequently the 
various acyl-chlorides were added. A catalytic amount of DMAP was used and a solid 
phase-supported amine (PS-DIEA) added to capture HCl released in the reaction 
mixture. Resulted products D1-D19 are showed in Table 7.2. 
Preparation of compound D16 and D18 as seen before for the related 
sulphonamidic compounds, required a different synthetic procedure showed in Scheme 
12.2.  
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Scheme 12.2: Synthesis of compound D16 and D18 
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 Compound 21.2c and 21.2d in fact were treated with phenylboronic acid in a 
cross coupling reaction in the presence of Pd(PPh3)4 to yield the secondary amine 21.2e 
and 21.2f  that was therefore treated with benzoyl chloride and catalytic amounts of 
DMAP and PS-DIEA to produce the desired compound D16 and D18 in good yields. 
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BACE inhibition assay of 4-aminopiperidine derivatives 
 
Tables 1.2-5.2 show all the synthesized compounds A-D and their percentage of 
inhibitory activity on BACE, when tested with the TR-FRET technology at the highest 
concentration of 20  M. 
 
 
 
Table 1.2:Compounds A1-A3 
  
 
* No activity detected up to  20 M 
 
 
Table 2.2:Compounds B1-B6 
 
 
 
 
 
* No activity detected up to  20 M 
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Table 3.2:Compounds C1-C14  
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                     * No activity detected up to  20 M 
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Table 4.2:Compounds C16 and C15  
 
 
 
 
 
 
 
* No activity detected up to  20 M 
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Table 5.2: Compounds D1-D19 
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* No activity detected up to 20 M 
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On the basis of the data resulting from biological tests we can point out that the 
presence of inhibitory activity on BACE of the herein reported 4-aminopiperidines 
seems to be essentially correlated with the presence of a benzylamine moiety. Aniline 
derivative A and B in Table 1.2 and 2.2 did not show any activity whatsoever. 
Moreover, it is clear that the sulphonilic group represents an essential portion 
within this series of compounds in order to have activity. As a matter of fact all the three 
active compounds C7, C11, C12 are sulphonamido derivatives, although they  show 
only a modest percentage of activity at the highest concentration of 20  M (Table 3.2), 
whereas the benzamido derivatives are devoid of any inhibitory properties (D1-D19, 
Table 5.2). 
Another common feature to all the active compounds C7, C11, C12 is the 
presence of a Boc group. In fact, the analog of C7 which is devoid of the N-Boc portion, 
that is compound C16 has no inhibitory activity up to a concentration of 20 µM (Table 
4.2). 
Finally, the activity may be associated with the steric hindrance of the two 
aromatic scaffolds and with their respective position inside the molecule. In fact, some 
activity is only found when at least three phenyl rings are present, as in compounds C7 
and in C11 where a para-phenyl or a meta-phenyl benzylic portions are respectively 
present, accompanying the remaining benzene-sulfonyl moiety. In C12, a para-phenyl 
benzene-sulfonyl substituent coexists with the single ring benzylamino portion, 
summing up a total of three aromatic rings, here again. On the other hand, when only 
two aromatic rings are present, as in the sulfonamido derivatives C1-C5 the BACE 
inhibitory activity is lost (Table 3.2). 
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Tetraline derivatives 
 
In the present section of the PhD thesis we report the synthesis of non 
peptidomimetic derivates potentially active on BACE planned using compound 3.2 in 
Figure 11.2 as a starting point. 
 
Figure 11.2 
 
N
O
Takeda
3.2
 
 
 
In particular, during the exam of the patent we noticed that the side chains in the 
general structure of the patent (Figure 12.2) were extensively represented and varied, 
while the central core AB of the generic structure in Figure 12.2 was only represented 
by the three substructures showed below. 
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Figure 12.2: Generic structure of Takeda compound and the three claimed 
substructures. 
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On these basis we therefore planned new molecules inserting different 
heterocycles or other moieties instead of the tetralinic core of Takeda compound (Figure 
13.2) with the aim of increasing the polarity of the patented compound that possesess a 
good value of IC50 but most likely cannot be developed as a drug because of its 
accentuated lipofilicity that can  compromise oral bioavailability. 
The insertion of heteroatoms like oxygen, nitrogen and sulphur inside the core 
should increase the polarity and accordingly improve the ability to cross the blood-
brain-barrier that represent the most important obstacle for CNS drugs. 
Figure 13.2 
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,
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We designed molecules in which the biphenylic scaffold present in the original 
molecule was maintained and we made changes in the amino moiety. We inserted 
alternatively the piperidine ring, already present in the patent but also a dimethylamino  
group already present in a further compound reported in the patent that possessed a 
higher value of IC50 in comparison to compound 3.2 in Figure 11.2 but that was 
definitely more lipofilic. We therefore designed new structures using both the 
combinations.  
With the aim of explore in details the new projected molecules, compounds 
planned were also profiled for their predicted physicochemical properties131 to give 
good pharmacokinetic and CNS permeability parameters.  
All compounds designed were therefore submitted to a theoretic analysis basing 
on the Lipinski, Veber and Norinder’s rules using Spotfire2 program in Siena Biotech 
Laborartories. In the ambit of this study, restrictions of three of the most important 
parameters RBN (number of rotatable bonds), MlogP (parameterization of the 
hydrophobicity) and BBB (blood-brain barrier permeability) were made to their 
optimum value in order to obtain compounds with better physicochemical properties. 
Approximately 80 compounds were planned and designed in our research 
laboratory and for each one the synthetic feasibility was definite as a result of a detailed 
bibliographic research. Among these compounds we finally selected for our study  the 8 
compounds showed in Figure 14.2. 
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 Figure 14.2: New structures related to Takeda disclosed compounds 
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Among compounds showed in Figure 14.2 compounds E and F1 and F2 in Figure 
15.2 have been finally chosen as the best candidates for development on the basis of 
their synthetic feasibility and their calculated CNS permeability parameters.  
 
Figure 15.2 
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The indane E and the isoprenoid derivatives F1 and F2 have been finally 
synthesized. 
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Considering the structural similarity between compound E and compound 3.2 we 
planned his preparation on the basis of the synthetic procedure described for the 
patented compound making some synthetic modifications where necessary. 
 Derivate E was therefore prepared in seven steps as shown in Scheme 13.2.  
 
Scheme 13.2: Synthesis of compound E 
 
 
OMeO O
O
OEt
MeO
LHMDS/BrCH2COOEt
HMPA/THF
NaOH
EtOH
O
O
OH
MeO
NHMe2
O
O
N
MeO
CH3
CH3
NaBH4
TsOH
Toluene O
N
MeO
CH3
CH3
O
N
MeO
CH3
CH3
H2/Pd/C
LiAlH4
N
MeO
CH3
CH3
BBr3, DCM
N
O
CH3
CH3
Cl
1)
2)
1)
 NaH 60%, DMF2)
23.2
24.2 25.2
27.2
28.2
22.2
26.2
E
 
Commercially available 5-methoxy-1-indanone 22.2 was esterified with 
BrCH2COOMe
132 in the presence of LHMDS to obtain the desired ester 23.2 in good 
yield. The following hydrolysis of 23.2 with NaOH in EtOH yielded acid 4.2 and 
amidation reaction of 24.2 with N,N-dimethylamine produced amide 25.2. The 
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following reduction-elimination reaction of compound 25.2 with NaBH4 and p-TsOH 
resulted in the formation of indene derivative 26.2. The catalytic hydrogenation of 26.2 
followed by reduction of the remaining amide 27.2 with LiAlH4, afforded the desired 
amino derivative 28.2. Finally, deprotection reaction of compound 28.2 with BBr3 
followed by etherification with 4-phenylbenzyl chloride in the presence of NaH 60% 
produced the desired aminoalkyl-substituted indane E in good yield. 
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In order to make further structural modifications in the central core of the patented 
compound reported from Takeda company, a non cyclic scaffold instead of the tetralinic 
one was designed. We therefore accomplished the synthesis of derivatives F1 and F2 
using synthetic procedures already developed in our research laboratory. 
Compounds F1 and F2 were synthesized in six steps starting from commercially 
available 3-methyl-2-buten-1-ol 29.2 as shown in Scheme 14.2. 
 
Scheme 14.2: Synthesis of compounds F1 and F2 
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The hydroxyl group of alcohol 29.2 was protected by reaction with 3,4-
dihydropyran and pyridinium p-toluenesulfonate (PPTs)133 to generate a 
tetrahydropyranyl ether in high yield. The resulting ether 30.2 was oxidized with tert-
butylhydroperoxide and catalytic H2SeO3 in the presence of and salicylic acid to obtain 
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compound 31.2 that was then treated with NaH 60% and 4-phenylbenzyl chloride in a 
DMF solution to generate compound 32.2.  
After deprotection reaction of 32.2 with pyridinium p-toluenesulfonate in EtOH, 
the resulting alcohol 33.2 was then treated with chloroethyl N,N-dimethylamine or 
chloroethyl piperidine in the presence of K2CO3 to respectively obtain the two desired 
final compounds F1 or F2 in good yield.  
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BACE inhibition assay of E, F1 and F2 
 
Compounds E, F1 and F2 were submitted to biological tests with the TR-FRET 
technology at Siena Biotech laboratories and compounds E showed an inhibitory 
activity on BACE in the  M  range (Table 6.2).  
 
 
Table 6.2 
 
 
The shrinkage of the saturated ring of the Takeda compound from a six- to a five-
member ring, as in the indane derivative E, preserved the good inhibitory properties of 
the molecule. On the contrary, the replacement of the bicyclic core portion with an 
acyclic isoprenoid moiety caused the loss of activity, as in compounds F1 and F2. 
N
CH3
CH3
O
CH3
O
O
N
CH3
O
O
N
CH3
CH3
N
O
IC50(µM)Compound
>20
F2
>20
F1
12
E
11
3.2
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Carbazole derivatives 
 
 
In order to find other new potential hits as BACE inhibitors, a considerable 
number of available compounds were screened at Sienabiotech Laboratories. During the 
screening, three carbazole derivatives 4.2-6.2 in Figure 16.2 were discovered to have 
interesting biological results, showing an inhibitory activity on BACE in the 
micromolar range. 
Figure 16.2 
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In order to explain the activity of compounds 4.2, 5.2 and 6.2 docking studies 
have been carried out at Siena Biotech laboratories and were performed using the X-ray 
structure from the Protein Data Bank: 1FKN.  
In the protease family the binding site is usually mapped using a sub-pocket 
organization. The binding site is considered to be divided in two main regions defined 
by the cutting point of the substrate peptide. The binding site part that recognizes the C-
terminus region of the peptide is called prime region (S’) in Figure 17.2. The side at the 
N-terminus of the peptide is termed non-prime region (S). The two regions are mapped 
in sub-pockets starting from the cutting point towards the periphery of the substrate 
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peptide. The S2’, S1, and S2 pockets were mainly involved in lipophilic interactions. 
On the contrary, S1’ and S4 pockets were mainly involved in hydrophilic interactions. 
 
Figure 17.2: BACE Binding Site Map. 
 
The main pockets of the BACE 
binding site are shown in this 
schema. For each pocket  
hydrophilic interactions are also 
shown. 
In red:  the catalytic aminoacids 
Asp32 and Asp228 activate a 
water molecule that functions as 
the nucleophile responsible for 
amide cleavage:  
 
 
 
 
 
 
 
 
                     3D Binding Site Map of BACE on 1FKN co-crystal structure.  134 
 
On these basis, two putative binding modes based on docking calculation were 
hypothesized. Due the high pseudo-symmetry of this class of molecules two opposite 
binding modes were found (A and B in Figures 18.2 and 19.2).
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Figure 18.2: Carbazole binding mode A 
 
 
 
 
 
 
 
 
 
 
 
Figure 19.2: Carbazole binding mode B 
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 With the aim of guiding the exploration of this class, new compounds related to 
the carbazole scaffold have been planned in our laboratory. In particular, taking 
compounds 4.2 and 5.2 as a reference, we accomplished the synthesis of new 
compounds G, H, J, K showed in Figure 20.2. 
 
Figure 20.2: New carbazole derivatives 
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Compounds G, H, J, K are characterized by the presence of a carbazole moiety 
and differ on the basis of the presence of an aryl amidic (H, K) or a aryl sulphonamidic 
(G, J) functionalities. Furthermore, we made some structural modifications on the 
amino moiety by inserting several groups R1 and R2 represented by variously 
substituted aryl scaffolds.  
Compounds J and K differ from previous compounds G and H (Figure 23.2) for 
the presence of a benzylamine portion linked to the N atom of the side chain of the 
molecule instead of the arylic one present in G and H derivatives. In particular, 
compounds J are aryl sulphonamidic derivatives while compounds K are aryl amidic 
derivatives. In both compounds J and K the aromatic scaffold can be substituted with 
R2 groups.  Moreover, the carbazole moiety of compounds J and K can contain an 
halogen substituent (R3).  
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Carbazole derivatives G1-G7 were synthesized following the procedure shown in 
Scheme 15.2. 
 
 
Scheme 15.2: Synthesis of compounds G1-G7 
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The various carbazole derivatives were easily prepared in a parallel way in three 
steps starting from commercially available carbazole 35.2 that was initially alkylated 
with epichloridrine in the presence of KOH to give the desired epoxide 36.2 in good 
yields. Subsequently the epoxide 36.2 was opened by reaction with various anilines in 
cyclohexane at room temperature in the presence of BiCl3 as the catalyst and the 
secondary amines 37.2a-f were easily obtained in excellent yields by crystallisation 
from Et2O. The reaction of products 37.2a-f with the appropriate differently p-
substituted aromatic sulfonyl chloride led to the final compounds G1-G7. For all the 
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coupling reactions we used PS-DIEA (a solid phase-supported amine) to capture HCl 
released in the reaction mixtures, and DMAP as the catalyst.  
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The synthetic procedure followed for derivatives H1-H9 is showed in Scheme 
16.2. 
 
Scheme16.2: Synthesis of compounds H1-H9 
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Secondary amines 37.2a-f, obtained as shown in Scheme 15.2, were submitted to 
condensation reactions with appropriate differently p-substituted  aromatic aroyl 
chloride to yield compounds H1-H9. Also in this case we used a solid phase-supported 
amine (PS-DIEA) to capture HCl released in the reaction mixtures and DMAP as the 
catalyst. 
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The synthesis of sulphonamidic derivatives J1-J7 followed the synthetic 
procedure already described for the previous series and is shown in Scheme 17.2. 
 
 
Scheme 17.2: Synthesis of compounds J1-J7 
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N
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R3
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O
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R1
J1 R1=H, R2=H
J2 R1=H, R2=p-Me
J3 R1=H, R2=p-Cl
J4 R1=H, R2=p-OMe
J5 R1= p-Me, R2=H
J6 R1= p-Cl,   R2=H
J7 R1= p-OMe ,R2=H
 38.2a
 38.2b
 38.2c
 38.2d
R1=H     
R1=p-Cl    
R1=p-Me  
R1=p-OM
e 
R3 =H
R3 =H
R3 =H
R3 =H
36.2
 
Carbazole derivatives J1-J7 were easily prepared from epoxide 36.2 which was 
synthesized as seen above (Scheme 15.2). Epoxide 36.2 was opened by reaction with 
various p-substituted benzylamines in EtOH at room temperature and secondary amines 
38.2a-d were easily obtained in excellent yield by crystallisation from Hexane/Et2O. 
The reaction of products 38.2a-d with the appropriate differently p-substituted aromatic 
sulfonyl chloride led to the final compounds J1-J7. As usual for all the coupling 
reactions we used PS-DIEA to capture HCl released in the reaction mixtures and 
catalytic amounts of DMAP.  
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Compounds J8-J11 were, on the contrary, synthesized starting from commercially 
available di-chlorocarbazole 39.2, following the same procedure seen above as shown in 
scheme 18.2.  
 
Scheme 18.2:Synthesis of compounds J8-J11 
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39.2 40.2
J8 R1=H, R2=H
J9 R1=H, R2=p-Me
J10 R1=H, R2=p-Cl
J11 R1=H, R2=p-OMe
 41.2a 
 41.2b
 41.2c
 41.2d
R1=H
R1=p-Cl
R1=p-Me
R1=p-OMe
 
Commercially available carbazole 39.2 that was initially alkylated with 
epichloridrine in the presence of KOH to give the desired epoxide 40.2 in good yields. 
Subsequently the epoxide 40.2 was opened by reaction with various p-substituted  
benzylamines in EtOH at room temperature and the secondary amines 41.2a-d were 
easily obtained in excellent yields by crystallisation from Et2O and cyclohexane. The 
reaction of products 41.2a-d with the appropriate differently p-substituted aromatic 
sulfonyl chloride led to the final compounds J8-J11
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Compounds K1-K7 were synthesized as showed in Scheme19.2.  
 
Scheme 19.2:Synthesis of compounds K1-K7 
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K2 R1=H, R2=p-Cl
K3 R1=H, R2=p-OMe
K4 R1=H, R2=3,4 Cl
K5 R1= p-Me, R2=H
K6 R1= p-Cl,   R2=H
K7 R1= p-OMe ,R2=H
 
The various carbazole derivatives K1-K7 were prepared in a parallel way starting 
from epoxide 36.2, prepared as seen before (Scheme 15.2). Epoxide 37.2 was opened by 
reaction with variously p-substituted  benzylamines in EtOH at room temperature and 
secondary amines 41.2a-d were easily obtained in excellent yields by crystallisation 
from Et2O. The reaction of products 41.2a-d with the appropriate differently p-
substituted aromatic acyl chlorides yielded compounds K1-K7, under the usual 
conditions.  
 94 
BACE inhibition assay of carbazoles G, H, J and K 
 
 
The various carbazole derivatives G-K obtained during this PhD research work 
and their IC50 values measured by the TR-FRET assay are shown in Tables 7.2-11.2. 
 
Table 7.2: Compounds G1-G7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N
OH
NS
OO
R2
R1
G
3.8p-NO2G6
p-F
p-CF3
p-Cl
p-Me
> 10G7
3.6G5
>10G4
7.1
H 
G3
2.4p-MeOG2
2.9p-ClG1
2.6p-Me4.2
3.0H
H
5.2
IC50  µMR2R1Compd
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Table 8.2: Compounds H1-H9 
 
 
  
 
 
 
 
 
 
 
 
 
As showed in Tables 7.2 and 8.2 aniline-type sulphonamide derivatives G display 
a general trend of appreciable activities on BACE comparable to the reference 
compounds 4.2 and 5.2.  For these compounds the activity is maintained for almost 
every substitution of R1 and R2. On the contrary, the related aniline carboxamido 
compounds H showed in Table 8.2 show inhibitory activities on BACE only when the 
benzamidic portion is substituted (R2 ≠ H). 
 
 
 
 
 
 
 
N
OH
N
O
R2 H
R1
>10p-NO2H8
p-F
p-CF3
p-Cl
p-Me
>10H9
>10H7
>10H6
>10
H 
H5
2.43,4 ClH4
3.8p-OMeH3
4.7p-ClH2
>10H
H
H1
IC50  µMR2R1Compd
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Table 9.2: Compounds  J1-J11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21.2: Compounds K1-K7 
 
            
 
IC50 > 10 µM
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2.3p-MeJ9
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p-Me
H
R2
p-Cl
p-Me
0.9J11
2.7J6
>10J5
1.6J4
1.7
H
J3
2.7J2
1.9
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IC50  µMR3R1Compd
K1 R1=H, R2=H
K2 R1=H, R2=p-Cl
K3 R1=H, R2=p-OMe
K4 R1=H, R2=3,4 Cl
K5 R1= p-Me, R2=H
K6 R1= p-Cl,   R2=H
K7 R1= p-OMe ,R2=H
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For benzylamine derivatives J and K  showed in Tables 9.2 and Figure 21.2  the 
trend of activity on BACE is similar to the previous aniline-type compounds showed in 
Tables 7.2 and 8.2. In this case the situation is emphasized because only sulphonamido 
derivatives J in Table 9.2 show significant values of IC50 in the micromolar range, while 
the corresponding carbonyl derivatives K, on the contrary, did not show any activity at 
the highest concentration of 10µM. Moreover, it should be noticed that benzylamine-
sulfonyl derivatives J generally showed slightly better inhibitory properties than their 
aniline-counterparts G. 
In details, also in this case among various R2-substituents on the 
benzenesulphonamido ring, chloro and methoxy groups are associated with the most 
active inhibitors. Actually, the two most active compounds in Table 9.2 resulted to be 
the p-chlorobenzyl- (J3) and p-methoxybenzyl- (J4) substituted sulphonylic derivatives, 
which showed  inhibitory activities on BACE of 1.7 and 1.6 µM, respectively.  
The insertion of chlorine atoms into the carbazole moiety (R3 = Cl) of the 
sulfonamidic derivatives afforded efficient inhibitors only when it was associated with 
the concomitant presence of electron-donating substituents in the benzene-sulfonyl ring, 
such as a p-methyl in J9 or a p-methoxy in J11, whereas unsubstituted (J8) or p-chloro-
substituted (J10) derivatives resulted to be inactive (Table 9.2). In particular the lowest 
IC50 value of the whole series was found for di-chlorocarbazole derivative J11, (R2 = p-
methoxy), whose value was as low as 0.9 µM.  
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N
OH
NH
R1
41.2a
41.2b
41.2c
41.2d
R1=H   
R1=p-Cl    
R1=p-Me   
R1=p-OMe 
Biological tests were made also for the synthetic precursors of compounds G and 
H, that are, the various secondary amines 42a-d (Figure 22.2). When these compounds 
were tested with TR-FRET assay at the highest concentration of 20 µM, none of them 
showed a significant inhibitory activity on the enzyme. 
Figure 22.2 
 
 
 
 
 
    IC50 > 10 µM 
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 As a continuation of these studies and based on the good inhibitory activity on 
BACE of the di-bromocarbazole derivative 6.2 (see Figure 16.2, IC50 =1.1 µM), we 
therefore accomplished the synthesis of other derivatives related to the carbazole series, 
still maintaining as a constant portion the α-naphthylamine moiety.  
Also in this case in order to explain the activity of compound 6.2, docking studies 
have been carried out at Siena Biotech laboratories and were performed using the X-ray 
structure from the Protein Data Bank: 1FKN.  
 Figure 23.2 shows the two opposite hypothesized binding modes A and B for 
compound 6.2 on  the basis of docking calculation. 
 
Figure 23.2 : Binding mode A and B hypotized for compound 6.2 
            Binding mode A                                               Binding mode B 
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Taking compound 6.2 (Figure 24.2) as the reference and with the aim of initially 
exploring the role of the two halogen atoms in the carbazole scaffold of this compound,  
the unsubstituted carbazole derivative L and the di-chloro substituted M were 
synthesized. Furthermore other compounds, N-P (Figure 24.2,) were synthesized in 
which the carbazole moiety was replaced with indole (compound N), 2-phenylindole 
(compound O) and 5-methoxy, 2-phenyl indole (compound P) moieties. 
Figure 24.2: New carbazole derivatives 
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The syntheses of L and M were done on the basis of the synthetic procedures 
previously described for other carbazole derivatives and are shown in Schemes 20.2 and 
21.2. 
 
Scheme 20.2: Synthesis of compound L 
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Epoxide 36.2, synthesized as reported in Scheme 15.2, was submitted to a ring-
opening reaction with 1-naphtylamine in cyclohexane and in the presence of BiCl3 as 
the catalyst and compound L was easily obtained in excellent yields by crystallisation 
from Hexane/Et2O (Scheme 20.2). 
 
 
Scheme 21.2:Synthesis of compound M 
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Synthesis of M started from commercially available carbazole 39.2 which was 
alkylated with epichloridrine in the presence of KOH to give the desired epoxide 40.2 in 
good yields. As seen before, epoxide 40.2 was then opened by reaction with 1-
naphtylamine in  cyclohexane and in the presence of BiCl3 as catalyst and compound  
M was obtained in excellent yields by crystallisation from Hexane/Et2O (Scheme 21.2).  
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Compounds N-P in Figure 24.2 were synthesized following the generic procedure 
showed in Scheme 22.2 using parallel methodologies as seen above for other derivatives 
previously described. 
 
Scheme 22.2:Generic synthetic procedure for compounds N,O,P. 
 
 
Cl O
KOH/DMF BiCl3
NH2
Cyclo hexane
N
H
R
R'
N
R
R'
O
N
R
R'
OH
NH
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45 R=H, R'=Ph         
46 R=OMe, R'=Ph  
      
48 R=H,R'=H            
49 R=H,R'=Ph         
50 R=OMe, R'=Ph   
     
N R=H,R'=H           
O  R=H, R'=Ph         
P  R=OMe, R'=Ph   
     
 
Commercially available indoles 44-46 were alkylated with ephychloridrine in the 
presence of KOH to give the desired epoxides 48-50 in good yields. Epoxides 48-50 
were then opened by reaction with 1-naphtylamine in cyclohexane and in the presence 
of BiCl3 as the catalyst. Subsequent crystallisation from Hexane/Et2O afforded 
compounds N-P in excellent yields.  
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BACE inhibition assay of derivatives L-P 
 
All synthesized compounds L-P were submitted to biological tests with the TR-
FRET technology at Siena Biotech laboratories. The IC50 values calculated for 
synthesized compounds are showed in Table 11.2.  
Table 11.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
>10
N
1.6
O
(IC50µM)Compound
>10
P
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3.0
L
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N
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N
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N
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Br
OH
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Available data resulting from biological screening of synthesized compounds L-P 
showed inhibitory activities for these derivatives comparable to the reference compound 
6.2. Considering in details derivatives L and M in which the carbazole moiety was 
maintained, it should be noticed that the removal of Br atoms in the heterocyclic 
scaffold of the molecule caused a slight decrease of activity on BACE: the unsubstituted 
carbazole derivative L (Table 11.2) in fact showed an IC50 value of 3.0µM. On the 
contrary, the replacement of the original Br atoms with Cl substituents in the carbazole 
moiety afforded a noticeable improvement of activity: in fact the lowest IC50 value of 
the whole series of synthesized compounds was found for the di-chlorocarbazole 
derivative M whose value was as low as 0.5 µM. 
Among indoles derivatives N-P, only 2-phenyl indole derivative O (Table 11.2) 
showed an appreciable value of inhibitory activity on BACE exhibiting an IC50 value of 
1.6 µM. On the contrary, the unsubstituted indole derivative N and the 5-methoxy, 2-
phenyl indole derivative P did not show a significant inhibitory activity on the enzyme.  
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Chapter 3 
 
 107 
 Biological  assay 
 
 
All compounds synthesized during this PhD have been tested with a time resolved 
fluorescence quenching assay at Siena Biotech laboratories. The principle of the assay 
used for tests is shown in Figure 1.3. 
 
Figure 1.3: Principle of TR-FRET assay. 
(Time Resolved-Fluorescence Resonance Energy Transfer) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
An Eu+ chelate is coupled to the N terminus and a quenching organic fluorophore 
(Q) to the C-terminus of the peptide containing the Amyloid Precursor Protein Swedish 
mutation (underlined in white). The proteolitic cleavage of the substrate interrupts the 
energy transfer between the donor-acceptor pair and, upon excitation at 330 nm, 
produces a linear increase of emitted fluorescence at 615 nm. The fluorescence emitted 
is directly related to the enzymatic activity and can be followed by continuous TRF 
measurements.  
Q
Eu
Eu
Q
330 nm
330 nm
615 nm
BACE1
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Chapter 4 
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Experimental section 
 
 
General details 
 
Proton NMR spectra were recorded on a Bruker AC 200 (200 MHz) spectrometer 
as dilute solutions in deuterochloroform. The chemical shifts are recorded relative to 
tetramethylsilane as internal standard and the multiplicity of the signals is designated by 
one of the following abbreviations: s, singlet; d, doublet; t, triplet; q, quartet; quin, 
quintet; br, broad; m, multiplet; with all various possible combinations (e.g. dd is double 
doublet). All coupling constants J, are reported in Hertz.  
Flash chromatography was performed on Merck silica gel 60 or on Isolute pre-
packed silica columns and Isolute ionic exchanged pre-packed silica column as the 
stationary phase and the solvents employed were either of analytical grade or were 
distilled before the use.  
All reactions were monitored by TLC using Merck silica gel 60 F24 pre-coated 
aluminium backed plates which were visualised with ultraviolet light and/or basic 
potassium permanganate solution and phosphomolybdic acid. 
Dry organic solvents were stored under nitrogen and/or over sodium wire. The 
organic solvents were dried by distillation from the following: dichloromethane, 
pyridine, triethylamine, acetonitrile from calcium hydride; methanol from magnesium 
methoxide; benzene, toluene, THF and diethyl ether from sodium metal. N,N-
dimethylformamide (DMF) Dimethylsulfoxide (DMSO) were purchased from Aldrich 
in SureSeal containers. 
All other commercially available reagents were used as received from Fluka, 
Sigma-Aldrich, Merck, Lancaster. 
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Solvents were removed by rotary evaporation in vacuo. 
Where necessary, reaction requiring anhydrous conditions were performed in a 
flame or oven-dried apparatus under a nitrogen atmosphere. 
All LCMS analyses were carried out using a Waters Alliance HT 2795 instrument 
with a Phenomenex C18 column and either a 5 or 10 minute gradient of 
acetonitrile/water containing 0.1% formic acid. 
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Actelion compound 
 
 
Synthesis of compound 8.2 
 
   
N
O
bn
N
bn
OH
PhMgBr, Et2O
reflux
7.2 8.2  
To a three neck flask under nitrogen with Mg (1.08g, 44.4 mmol) and I2 (cat) and 
Et2O (5 ml) a solution of Phenyl-bromide (5.80g, 36.9 mmol) in Et2O (15 ml) was 
added dropwise. The mixture was refluxed for 0.5h. Then a solution of N-benzyl-
piperidone 7.2 (2.00 g, 10.5 mmol) in Et2O (30 ml) was added dropwise. The mixture 
was refluxed for 1h and then left overnight at room temperature and then NH4Cl was 
added dropwise to neutralise the unreacted Mg. The product was extracted with CHCl3 
and the organic phase was evaporated under vacuum to give the desidered product  
(3.38g) as a yellow oil (99% yield). 
 1H NMR (200 MHz) CDCl3: δ, 1.74 (dd, 2H, J= 14.1 and 2.5 Hz), 2.50 (td, 2H, J=12.0 
and 2.2Hz), 2.81 (td, 2H, J= 13.0 and 4.3 Hz), 2.81 (dd, 2H, J= 8.8 and 2.2 Hz,), 3.60 
(s, 2H), 7.65-7.16 (m, 10H); 
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 Synthesis of compound 9.2 
N
bn
OH
H2SO4
CH3COOH glacial
N
bn
solution 20%
8.2 9.2  
N-benzyl-4-phenyl-4-hydroxy-piperidine 8.2 (3.38g, 12.65 mmol) was treated with 
H2SO4 in CH3COOH sol 20% (50 ml). The reaction mixture was stirred for 1h at room 
temperature and then NaOH 1N was added until the pH was adjust to basicity. The 
desired product was extracted with Et2O and evaporated under vacuum. The crude was 
purified with flash chromatography (8:2 Hexane/AcOEt) to give a yellow oil (1.64g, 
51.7% yield). 
1H NMR (200 MHz) CDCl3: δ 2. 61-2.47 (m, 2H), 2.72 (t, 2H, J= 5.20 Hz), 3.18 (dd, 
2H J= 6.0 and 2.70 Hz), 3.65 (s, 2H) , 6.14 -6.00 (m, 1H), 7.58-7.18 (m, 10H); 
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Synthesis of compound 10.2 
 
N
bn
9.2
THF
H2O2
N
bn
OH
Borane- methyl sulfide
 complex
1)
10.2  
To a solution of olefine 9.2 (1.1g, 4.41 mmol) in THF (14 ml) BH3-sulfide-complex 
(4.4ml, 8.8 mmol) was added dropwise and the reaction mixture was allowed to warm 
to reflux for 2h. After cooling to 0°C NaOH 1N (11 ml) was added dropwise and then 
H2O2 dropwise (16.5 ml). The reaction was allowed to warm to 100°C and stirred for 
2h. After cooling to room temperature Et2O was added  and the reaction mixture was 
washed with NaOH 1N, Na-tiosulfate sol sat. and NH4Cl sol sat. The organic phase was 
collected and evaporated in vacuo and a yellow solid was obtained. Purification by flash 
chromatography (1:1 Hexane/AcOEt) afforded a white solid (800 mg, 68% yield). 
 1H NMR (200 MHz) CDCl3: δ 1.48-1.63 (m, 2H), 1.75-2.17 (m, 4H), 2.31-2.50 (m, 
1H), 2.88-3.20 (m, 1H), 3.15-3.27(m, 1H), 3.60 (AB quartet, 2H, J= 15.90 and 13.10 
Hz), 3.78-3.96 (m, 1H), 7.20-7.40 (m, 10H); 
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Synthesis of compound 11.2 
N
bn
OH
Cl
O
Et3N, DMAP, CH3CN
N
bn
O
O
11.210.2  
N-benzyl-4-phenyl-3-hydroxy-piperidine 10.2 (520 mg, 1.94 mmol) was dissolved in 
CH3CN and biphenyl carbonil chloride (2.10g, 9.70 mmol), Et3N (2.11 ml, 15.52 
mmol), DMAP (cat) were added. The mixture was stirred overnight at room 
temperature, then it was quenced with H2O and NH4OH sol 30% and extracted with 
AcOEt. The organic phase was washed with NaHCO3 sol sat and evaporated under 
vacuum. Purification by flash chromatography (7:3 Hexane/AcOEt) afforded the 798 
mg (92% yield) of desired product as a yellow solid. 
1H NMR (200 MHz) CDCl3: δ 2.26-1.84 ( m, 4H) 2.93-2.75 (m, 1H), 3.04-2.93 (m, 
1H), 3.55-3.48 (m, 1H), 3.64 (dd, J= 21.40 and 13.10 Hz, 2H), 5.39 (td, J= 10.30 and 
4.60 Hz, 1H), 7.64-7.51 (m, 4H), 7.51-7.09 (m, 12H), 7.88 (AA’XX’, 2H, J= 8.40 and 
4.0 Hz);  
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Synthesis of compound 1.2 
N
bn
O
O
N
H
O
OH2/Pd
11.2 1.2
 
Compound 11.2 (200mg, 0.45 mmol) was dissolved in AcOEt (23 ml) and Pd /C 10% 
(281.1 mg, 0.60  mmol) was added. The reaction mixture was stirred under H2 for 15 
days and then filtered on Celite and washed with AcOEt. The organic phase was 
evaporated and purification by flash chromatography (9:1 Hexane/AcOEt) afforded the 
desired product (149 mg) as a white solid (80% yield). 
 1H NMR (200 MHz) CDCl3: δ 2.10-1.70 (m, 2H) 2.78-2.60 (m, 2H), 2.97 (td, 1H, J= 
11.30 and 3.80 Hz), 3.17 (d, 1H, J= 12.4 Hz), 3.50 (dd, 1H J= 11.70 and 4.50 Hz), 5.18 
(td, 1H, J= 10.31 and 4.5 Hz), 7.50-7.12 (m, 8H), 7.64-7.50 (m, 4H), 7.8 (AA’XX’, 2H, 
J= 8.42 and 4.01 Hz); 
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Takeda derivative 
 
Synthesis of compound 13.2 
 
O
MeO
O
MeO
CHCO2HCOH
CO2H
NaOH
12.2 13.2  
 
The commercial available  5- methoxy 1-tetralone 12.2 (5g, 28.37 mmol) was diluted in 
a solution of NaOH in water and dry EtOH and the glicossilic acid (5.22 g, 56.74 mmol) 
was added. The reaction was left under stirring under reflux for 18 h at 60 °C and than 
stopped after TLC analysis. The mixture was cooled and diluted with water Et2O and 
after treated with a HCl 2N solution. The resulting product, a yellow precipitate (5.1 g), 
was filtered and collected (78 %yield). 
1H NMR (200 MHz) CDCl3: δ 1.99-1.37 (m, 1H), 3.00 (t, 2H, J= 6.50), 3.43 (td, 2H, J= 
6.52 and 1.52 Hz), 3.88 (s, 3H), 6.72-6.75 (m, 1H), 6.91-6.85 (m,2H), 8.08 (d, 1H, J= 
8.67); 
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Synthesis of compound 14.2 
 
O
MeO
CHCO2H
MeO
CH2CO2H
Zn(Hg)
HCl conc
13.2 14.2  
 
The Clemmensen reactive was prepared with Zinc dust (20g, 300mmol) and HgCl2 
(2.10g, 7.73mmol) in the presence of HCl 37% (26 ml) and water ( 30 ml). The mixture 
was left under stirring for 30 minutes and the resulting Clemmnsen reactive was cooled 
at 0 °C and then water (6 ml), HCl ( 2ml), toluene (30 ml) and glacial acetic acid (2ml) 
were added. The acid 13.2 resulting from the first step (2.5 g,10.77 mmol) was then 
added to the previous solution and the mixture was stirred under reflux at 100°C for 4h. 
The mixture was cooled and diluted with water, wash with brine and finally extracted 
with Et2O. The resulting crude product 14.2, a pink solid (1.45g, 62% yield), was then 
used for the next reaction. 
1H NMR (200 MHz) CDCl3: δ 1.60-1.38 (m,1H), 1.90-1.60 (m,1H), 2.36-2.18 (m, 1H), 
2.51-2.38 (m, 2H), 2.85-2.79 (m, 3H), 2.93 (d, 2H, J= 14.62 Hz), 3.77 (s, 3H), 6.71-6.61 
(m, 2H), 6.97 (d, 1H, J= 8.24); 
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Synthesis of compound 15.2 
 
SOCl2, MeOH
OH
CH2CO2Me
MeO
CH2CO2H
HBr 48%
15.214.2  
 
The acid 14.2 (1.25 g, 5.68 mmol) was added to a HBr 48% ( 8.19 ml) solution and the 
mixture was heated to reflux at 160 °C and stirred for 4h. After TLC analysis, the 
mixture was cooled and diluted with water and extracted with AcOEt. The organic 
phase was washed with water and brine and than dried over Na2SO4 and concentrated. 
The resulting brown oil was diluted in MeOH (17 ml) and the reaction was left under 
stirring at 0 °C and than SOCl2 (856 mg, 7,20 mmol) was added dropwise to the 
mixture. The reaction was stirred at room temperature for 2h and stopped after TLC 
analysis: water and brine were added and the organic layer extracted, dried over Na2SO4 
and concentrated. The resulting product 15.2, a brown oil (1.10g, 88 % yield), was then 
used as a crude for the next reaction. 
1H NMR (200 MHz) CDCl3: δ 1.53-1.22 (m,2H), 2.02-1.85 (m, 1H), 2.48-2.33 (m, 3H), 
2.88-2.73 (m, 3H), 3.70 (s, 3H), 4.80 (s, 1H), 6.62-6.56(m, 2H), 6.90 (d, 1H, J= 8.06). 
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Synthesis of compound 16.2 
 
OH
CH2CO2Me
O
CH2CO2Me
Cl
NaH 60%, DMF
15.2 16.2
 
The alcohol 15.2 obtained from the previous reaction (1.10 g, 5.0 mmol) was dissolved 
in DMF( 25 ml) and cooled at 0 °C. NaH 60% (255 mg, 10.26 mmol) was added and the 
mixture was left under stirring at 40 °C for 1h and than cooled at 0 °C. Then 4-
phenylbenzyl chloride (1.11g, 5.47 mmol) was added and the reaction was stirred at 
room temperature for 15h and stopped after TLC analysis: water was added and the 
mixture extracted with AcOEt and than dried over Na2SO4 and concentrated. The 
resulting brown oil was purified by flash chromatography (1:1 Hexane/AcOEt). The 
purification afforded the desired product 16.2 (1.26g) as a yellow solid (65% yield). 
1H NMR (200 MHz) CDCl3: δ 1.58-1.22 (m,2H), 2.10-1.88 (m, 1H), 2.51-2.23 (m, 3H), 
2.92-2.79 (m, 3H), 3.70 (s, 3H), 5.07 (s, 2H), 6.82-6.70 (m, 2H), 6.98 (d, 1H, J= 8.05), 
7.63-7.35 (m, 9H). 
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Synthesis of compound 17.2 
 
O
OH
LiAlH4
THF
O
CH2CO2Me
17.2
16.2
 
 
Compound 16.2 (1.0g, 2.6 mmol) was added to a suspension of LiAlH4 (196 mg, 5.21 
mmol) and dry THF(15 ml) at 0 °C and the mixture was left under stirring at room 
temperature for 2h. After TLC analysis the mixture was diluted with water and treated 
with Sodium and Potassium tartrate and filtered on Celite and washed with AcOEt. The 
resulting product 17.2 , a white precipitate (940 mg), was collected ( > 98%yield).  
1H NMR (200 MHz) CDCl3: δ 1.71-1.25 (m, 5H), 2.0-1.78 (m, 1H), 2.39 (t, 1H, 
J=13.12 Hz), 2.90-2.77 (m, 3H), 3.86-3.74 (m, 2H), 5.06 (s, 2H), 6.80-6.70 (m, 2H), 
6.98 (d, 1H, J= 8.05), 7.62-7.34 (m, 9H). 
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Synthesis of compound 18.2 
 
O
OH
I2
THF, PPh3, imidazole
O
I
17.2 18.2  
 
A THF solution of compound 17.2 (940 mg, 2.62 mmol) was added to a solution of 
PPh3, (860mg, 3.29 mmol) dry THF( 30 ml), imidazole (210 mg, 3.0 mmol) and I2 (830 
mg, 3.26 mmol). After 1h the reaction was treated with water and extracted with AcOEt. 
The organic layers were washed with Na2S2O3 and brine and than dried over Na2SO4 
and concentrated. The crude product was purified by flash chromatography (Hexane). 
The purification afforded the desired product 18.2 (570 mg) as a white solid (47% 
yield). 
1H NMR (200 MHz) CDCl3: δ 1.50-1.25 (m, 1H), 2.02-1.84 (m, 4H), 2.43-2.29 (m, 
1H), 2.90-2.77 (m, 3H), 3.30 (t, 2H, J= 6.81 Hz), 5.06 (s, 2H), 6.80-6.70 (m, 2H), 6.98 
(d, 1H, J= 8.05),7.64-7.35 (m, 9H). 
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Synthesis of compound 3.2 
 
O
N
NH
DMF, K2CO3
O
I
3.218.2
 
 
A DMF solution of piperidine (213 mg, 2.5 mmol) and K2CO3 (430 mg) were added to 
product 18.2 ( 570 mg, 1.25 mmol) and the mixture was left under stirring for 40h at 
room temperature. After TLC analysis, the mixture was stopped: water was added and 
the resulting precipitate collected and extracted with AcOEt, dried over Na2SO4 and 
concentrated. The resulting crude was purified with by chromatography (95:15 
CHCl3/MeOHt). The purification afforded the desired product 3.2 (370 mg) as a white 
solid (72% yield) that was finally treated with HCl and Et2O to obtain the hydrochloric   
derivative. 
1H NMR (200 MHz) CDCl3: δ 3.12-1.70 (m, 19H), 3.62-3.44 (m, 2H), 5.06 (s, 2H), 
6.80-6.68 (m, 2H), 6.95 (d, 1H, J= 8.05), 7.62-7.34 (m, 9H). 
 
 
 
 123 
4- aminopiperidine derivatives 
 
 
General procedure for reductive amination 
 
 
N
O
boc
N
boc
N
H
Ar
CH2Cl2
CH3COOH , NaCNBH3
ArNH2
19.2  
  
To a solution of commercial N-Boc-4-amino-piperidine 19.2 (1 eq) in DCM (5 ml), the 
various aromatic amines (1.2 eq), sodium cyanoborohydride (1.2 eq) and acetic acid 
(2.50 eq) were added. The reaction mixtures were stirred at room temperature for 3 
hours. The desired secondary amines 21.2 and 21.2a-f were recovered from extractive 
work up and purification by SCX column.  
21.2 Yield 67 % 1H NMR (200 MHz, CDCl3) δ  1.43 (s, 9H), 1.95-1.76 (m, 4H); 2.80-
2.59 (m, 4H), 3.12-2.93 (m, 1H), 4.10-3.94 (m, 1H); 7.35-7.23 (m, 5H);  
21.2a Yield 67 % 1H NMR (200 MHz, CDCl3) δ  1.43 (s, 9H), 1.95 -1.76 (m, 4H); 2.84-
2.60 (m, 4H), 3.08-2.93 (m, 1H); 3.82 (s , 2H ), 4.10-3.94 (m, 1H); 7.38-7.22 (m, 5H);  
21.2b Yield 50 % 1H NMR (200 MHz, CDCl3) δ  1.45 (s, 9H), 1.56 -1.25 (m, 4H); 1.96-
1.81 (m, 2H), 3.86 (s , 2H ), 4.10-3.96 (m, 1H); 7.61-7.36 (m, 9H); 
21.2c Yield 27 % 1H NMR (200 MHz, CDCl3) δ  1.37-1.25 (m, 2H) ,1.44 (s, 9H), 1.92 -
1.78 (m, 2H), 2.88-2.57 (m, 3H), 3.79 (s, 2H ), 4.08-3.91 (m, 2H) 7.29-7.14 (m, 2H), 
7.40-7.35(m, 1H), 7.48 (s,1H); 
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21.2d Yield 55 % 1H NMR (200 MHz, CDCl3) δ  1.51-1.25(m, 2H) ,1.44 (s, 9H), 1.95 -
1.80 (m, 2H), 2.86-2.57 (m, 3H), 3.88 (s, 2H ),4.20-3.92 (m, 2H) 7.16-7.07 (dt, 1H, J= 
7.69 and 1.83 Hz), 7.41-7.23 (m, 2H), 7.53 (d,1H, J= 7.87 Hz); 
21.2e Yield 70 % 1H NMR (200 MHz, CDCl3) δ  1.38-1.19 (m, 2H) ,1.46 (s, 9H), 1.94 -
1.78 (m, 2H), 2.35 (s, 1H) 2.85-2.60 (m, 3H), 3.79 (s, 2H),4.10-3.94 (m, 2H), 7.56-7.15 
(m, 8H), 8.18 (d,1H, J= 6.41 Hz); 
21.2f Yield 70 % 1H NMR (200 MHz, CDCl3) δ  1.28-1.10 (m, 2H) ,1.43 (s, 9H), 1.68 -
1.57 (m, 1H), 2.50-2.36 (m, 1H) 2.80-2.62 (t, 2H, J= 11.31 Hz), 3.76 (s, 2H ), 3.96-3.82 
(m, 2H), 7.47-7.22 (m, 8H); 
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General procedure for cupping reactions 
CH2Cl2
PS-DIEA/DMAP
N
boc
N
H
Ar
N
boc
N Ar
X
Ar1
Ar1
XCl
X= SO2, CO
 
The desired secondary amine 21.2 and 21.2a-f (1eq) were dissolved in CH2Cl2 and the 
various acyl/sulfonyl-chlorides (1.10 eq), PS-DIEA (1.50 eq) and DMAP cat. were 
added. After one night at room temperature the amidic products  A, B, C and D were 
obtained from extractive work up and were purified by flash chromatography. 
A1 Yield 67 % 1H NMR (200 MHz, CDCl3) δ  1.37 (s, 9H), 1.95-1.76 (m, 1H), 2.75-
2.67 (m, 1H), 4.20-3.89 (m, 2H), 4.45-4.26(m, 1H); 7.35-7.23 (m, 5H); 7.73-7.42 (m, 
5H); 
A2 Yield 58 % 1H NMR (200 MHz, CDCl3) δ  1.36 (s, 9H), 1.77 (d, 2H, J= 11.72 Hz ), 
2.43 (s, 3H), 2.73-2.60 (m, 1H), 4.24-4.00 (m, 2H), 4.40-4.25 (m, 1H), 7.00-6.98 (m, 
2H), 7.29-7.24 (m, 2H), 7.38-7.30 (m, 3H), 7.60 (d, 2H, J= 8.42 Hz); 
A3 Yield 64 % 1H NMR (200 MHz, CDCl3) δ  1.38 (s, 9H), 1.77 (m, 2H), 2.69-2.57(m, 
1H), 4.22-3.98 (m, 2H), 4.41-4.23 (m, 1H), 7.23-7.00 (m, 2H), 7.76-7.30 (m, 6H); 
B1 Yield 67 % 1H NMR (200 MHz, CDCl3) δ  1.43 (s, 9H), 1.91 (d, 2H, J= 13.62 Hz), 
2.85 (t, 2H, J=11.42 Hz), 4.25-4.10 (m, 2H), 5.30-4.89 (m, 1H), 6.98-6.96 (m, 2H), 
7.24-7.10 (m, 8H); 
B2 Yield 53 % 1H NMR (200 MHz, CDCl3) δ  1.43 (s, 9H),1.46-1.52 (m, 2H), 1.89 (d, 
2H, J= 13.60 Hz), 2.21 (s, 3H), 2.84 (t, 2H, J= 11.36 Hz), 4.17-4.15 (m, 2H), 5.30-4.85 
(m, 1H), 7.02-6.88 (m, 4H), 7.17-7.11 ( d, 2H, J= 7.69 Hz ), 7.25-7.16 (m, 3H); 
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B3 Yield 68 % 1H NMR (200 MHz, CDCl3) δ  1.41 (s, 9H),1.44-1.55 (m, 2H), 1.89 (d, 
2H, J= 13.70 Hz), 2.85 (t, 2H, J= 11.42 Hz), 4.17-4.15 (m, 2H), 5.30-4.86 (m, 1H), 
7.08-6.96 (m, 2H), 7.17-7.08 ( m, 4H), 7.26-7.18 (m, 3H); 
B4 Yield 45 % 1H NMR (200 MHz, CDCl3) δ  1.40 (s, 9H),1.44-1.55 (m, 2H), 1.88 (d, 
2H, J= 13.56 Hz), 2.89-2.87 (m, 2H), 4.19-4.16 (m, 2H), 4.92-4.82 (m, 1H), 7.06-6.96 
(m, 2H),  7.17 (d, 1H, J= 8.43 Hz), 7.28-7.24 ( m, 4 H), 7.36 (d, 1H, J= 1.83 Hz); 
B5 Yield 58 % 1H NMR (200 MHz, CDCl3) δ  1.40 (s, 9H), 1.87 (d, 2H, J= 13.60 Hz), 
2.80-2.76 (m, 2H), 3.70 (s, 3H), 4.21-4.17 (m, 2H), 4.94-4.85 (m, 1H), 6.61 (d, 2H, J= 
1.90 Hz), 6.98 (d, 2H, J= 1.83 Hz), 7.23-7.19( m, 5H);  
C1 Yield 66 % 1H NMR (200 MHz, CDCl3) δ  1.46-1.43 (m, 4H), 1.65 (s, 9H), 2.56-
2.51 (m, 2H), 2.97 (d, 2H, J= 12.46 Hz), 3.90-3.76 (m, 1H), 4.45 (s, 2H) , 7.32-7.24 (m, 
3H),  7.37 ( d, 2H, J= 7.33 Hz ), 7.56-7.47 ( m, 3H), 7.82 ( d, 2H, J= 6.96 Hz ); 
C2 Yield 73 % 1H NMR (200 MHz, CDCl3) δ  1.48-1.41 (m, 4H), 1.39 (s, 9H), 2.56-
2.51 (m, 2H), 3.90-3.76 (m, 1H), 4.10-3.88 (m, 2H), 4.40 (s, 2H), 7.44-7.26 ( m, 5H), 
7.46 (AA’/XX’, 2H, JAX=8.45 and JAA’/XX’=2.2 Hz), 7.71 (AA’/XX’, 2H, JAX=8.45 and 
JAA’/XX’=2.2 Hz); 
C3 Yield 66 % 1H NMR (200 MHz, CDCl3) δ  1.35-1.25 (m, 4H), 1.38 (s, 9H), 2.43 (s, 
3H), 2.59-2.56 (m, 2H), 3.89-3.99 (m, 1H), 4.10-3.97 (m, 2H), 4.40 (s, 2H) , 7.32-7.24 
(m, 3H),  7.37 ( d, 2H, J= 7.33 Hz ), 7.37-7.23 ( m, 7H), 7.70 ( d, 2H, J= 8.42 Hz ); 
C4 Yield 73 % 1H NMR (200 MHz, CDCl3) δ  1.48-1.41 (m, 3H), 1.41 (s, 9H), 2.62-
2.57 (m, 2H), 3.82 (s, 3H), 4.10-3.90 (m, 2H), 4.37 (s, 2H), 7.38-7.26 ( m, 5H), 6.96 
(AA’/XX’, 2H, JAX=7.98 and JAA’/XX’=1.91 Hz), 7.75 (AA’/XX’, 2H, JAX=7.98 and 
JAA’/XX’=1.9 1Hz); 
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C5 Yield 45 % 1H NMR (200 MHz, CDCl3) δ  1.46-1.43 (m, 2H), 1.65 (s, 9H), 2.58-
2.55 (m, 3H), 3.01-2.98 (m, 3H), 4.03-3.79 (m, 1H), 4.43 (s, 2H) , 7.31-7.26 ( m, 5H), 
7.57-7.51 (m, 2H), 7.79 (s, 1H); 
C6 Yield 42 % 1H NMR (200 MHz, CDCl3) δ  1.38 (s, 9H), 1.55-1.44 (m, 4H); 2.70-
2.50 (m, 2H);  4.18-3.84 (m, 3H); 4.44 (s, 2H); 7.72-7.27 (m, 12H), 7.86 (d, 2H, J=8.4 
Hz); 
C7 Yield 35 % 1H NMR (200 MHz, CDCl3) δ  1.38 (s, 9H), 1.52-1.40 (m, 4H), 2.70-
2.51 (m, 2H), 4.10- 3.84 (m, 3H), 4.46 (s, 2H), 7.60-7.34 (m, 12H), 7.82 (d, 2H, J=6.59 
Hz ) ; 
C8 Yield 40 % 1H NMR (200 MHz, CDCl3) δ  1.41 (s, 9H), 1.76-1.50 (m, 4H), 4.25-
4.03 (m, 2H),  2.72-2.60 (m, 2H), 4.19-3.80 (m, 3H), 4.53 (s, 2H ), 7.14 (dd, 2H, J=8.6 
and 2 Hz ), 7.56-7.23 (m, 10H) ; 
C9 Yield 55 % 1H NMR (200 MHz, CDCl3) δ  1.52-1.36 (m, 4H), 1.39 (s, 9H), 2.72-
2.52 (m, 2H), 4.09-3.81 (m, 3H), 4.44 (s, 2H ), 7.26-7.12 (m, 2H), 7.61-7.35 (m, 9H)  
7.85-7.78 (m, 2H) ; 
C10 Yield 80 % 1H NMR (200 MHz, CDCl3) δ  1.38 (s, 9H), 1.60-1.54 (m, 4H), 2.74-
2.55 (m, 2H), 4.90-4.14 (m, 3H), 4.48 (sb, 2H ), 7.62-7.34 (m, 14H), 7.69 (AA’/XX’, 
2H, JAX=8.79 and JAA’/XX’=2.3 Hz), 7.87 (AA’/XX’, 2H, JAX=8.79 and JAA’/XX’=2.31 
Hz); 
C11 Yield 55 % 1H NMR (200 MHz, CDCl3) δ  1.61-1.21 (m, 4H), 1.37 (s, 9H), 2.67-
2.51 (m, 2H), 4.16-3.84 (m, 3H), 4.48 (s, 2H ), 7.57-7.34 (m, 9H)  7.85-7.81 (m, 2H) ; 
C12 Yield 80 % 1H NMR (200 MHz, CDCl3) δ  1.39 (s, 9H), 1.48-1.14 (m, 4H), 2.70-
2.57 (m, 2H), 4.09-3.97 (m, 3H), 4.40 (s, 2H ), 7.64-7.14 (m, 9H), 7.70 (AA’/XX’, 2H, 
JAX=8.40 and JAA’/XX’=2.51 Hz), 7.84 (AA’/XX’, 2H, JAX=8.40 and JAA’/XX’=2.51 Hz); 
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C13 Yield 58 % 1H NMR (200 MHz, CDCl3) δ  1.29-0.98 (m, 4H), 1.40 (s, 9H), 2.58-
2.36 (m, 2H), 3.98-3.67 (m, 3H),  4.35 (s, 2H), 7.55-7.15 (m, 12H), 7.78-7.70 (m, 2H), 
C14 Yield 54 % 1H NMR (200 MHz, CDCl3) δ  1.39 (s, 9H), 1.50-1.24 (m, 4H), 2.68-
2.56 (m, 2H), 4.10-3.96 (m, 3H), 4.51 (s, 2H ), 7.67-7.10 (m, 9H), 7.74 (AA’/XX’, 2H, 
JAX=8.60 and JAA’/XX’=2.31 Hz), 7.93 (AA’/XX’, 2H, JAX=8.60 and JAA’/XX’=2.31 Hz); 
D1 Yield 45 % 1H NMR (200 MHz, CDCl3) δ  1.36 (s, 9H), 1.70-1.46 (m, 4H), 3.31 (m, 
2H), 4.00-3.80 (m, 2H),  4.40-4.70 (m, 2H), 7.42-7.20 (m, 10H); 
D2 Yield 56 % 1H NMR (200 MHz, CDCl3) δ  1.36 (s, 9H), 1.75-1.56 (m, 4H), 2.80-
2.40 (m, 2H), 4.20-4.00 (m, 2H),  5.10-4.80 (m, 2H), 7.33-7.17 (m, 9H); 
D3 Yield 56 % 1H NMR (200 MHz, CDCl3) δ  1.40 (s, 9H),  1.58-1.56 (m, 4H), 2.35 (s, 
3H), 2.70-2.52 (m, 2H), 4.10-3.95 (m, 3H),  4.70-4.50 (m, 2H), 7.30-7.17 (m, 9H); 
D4 Yield 61 % 1H NMR (200 MHz, CDCl3) δ  1.41 (s, 9H),  1.65-1.62 (m, 3H), 3.80 (s, 
3H), 4.20-3.95 (m, 3H), 4.63 (s, 2H),  6.90-6.70 (m, 2H), 7.39-7.26 (m, 7H); 
D5 Yield 23 % 1H NMR (200 MHz, CDCl3) δ  1.42 (s, 9H),  1.80-1.62 (m, 4H), 2.60-
2.41 (m, 2H), 4.20-4.00 (m, 3H),  4.42-4.85 (m, 2H), 7.65-7.26 (m, 8H); 
D6 Yield 50 % 1H NMR (200 MHz, CDCl3) δ  1.42 (s, 9H), 1.85-1.52 (m, 4H), 2.90-
2.32 (m, 2H), 4.25-4.00 (m, 2H), 4.86-4.50 (m, 2H), 7.46-7.26 (m, 14H);  
D7 Yield 56 % 1H NMR (200 MHz, CDCl3) δ  1.40 (s, 9H),  1.58-1.56 (m, 4H), 2.80-
2.43 (m, 2H), 4.00-3.89 (m, 1H), 4.30-4.12 (m, 2H),  4.80-4.60 (m, 2H), 7.68-7.17 (m, 
9H); 
D8 Yield 47 % 1H NMR (200 MHz, CDCl3) δ  1.38 (s, 9H), 1.75-1.56 (m, 4H), 2.80-
2.40 (m, 2H), 3.89-3.80 (m, 1H), 4.20-4.00 (m, 2H),  4.80-4.60 (m, 2H), 7.50-7.10 (m, 
8H); 
D9 Yield 76 % 1H NMR (200 MHz, CDCl3) δ  1.36 (s, 9H), 1.80-1.62 (m, 6H), 2.40 (s, 
3H), 3.89-3.80 (m, 1H), 4.20-4.00 (m, 2H),  4.80-4.60 (m, 2H), 7.48-7.24 (m, 8H); 
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D10 Yield 44 % 1H NMR (200 MHz, CDCl3) δ  1.39 (s, 9H), 1.58-1.56 (m, 4H), 2.80-
2.40 (m, 2H), 3.82 (s, 3H), 4.40-4.12 (m, 2H), 4.60 (s, 2H), 7.26-7.20 (m, 2H), 7.37-
7.26 (m, 6H); 
D11 Yield 76 % 1H NMR (200 MHz, CDCl3) δ  1.36 (s, 9H), 1.80-1.50 (m, 6H), 2.87-
2.43 (m, 2H),  3.80-3.65 (m, 1H), 4.34-4.06 (m, 2H),  4.70-4.40 (m, 2H), 7.68-7.10 (m, 
7H); 
D12 Yield 60 % 1H NMR (200 MHz, CDCl3) δ  1.41 (s, 9H), 1.56-1.54 (m, 4H), 2.80-
2.43 (m, 2H), 4.20-4.00 (m, 2H); 4.80-4.50 (m, 2H), 7.67-7.35(m, 14H); 
D13 Yield 35 % 1H NMR (200 MHz, CDCl3) δ  1.41 (s, 9H), 1.80-1.65 (m, 3H), 2.54-
2.31 (m, 1H), 2.90-2.68 (m, 1H), 3.59-3.38 (m, 1H), 4.26-4.00 (m, 2H), 4.38 (s, 1H), 
4.75-4.64 (m, 1H), 4.77 (AB quartet, 2H, J=15.61 Hz), 7.14 (d, 2H, J=7.51 Hz ), 7.62-
7.30 (m, 10H); 
D14 Yield 35 % 1H NMR (200 MHz, CDCl3) δ  1.41 (s, 9H), 1.80-1.50 (m, 5H), 2.80-
2.40 (m, 1H), 4.21-4.01 (m, 2H), 4.62 (sb, 2H ), 7.20-7.08 (m, 2H), 7.60-7.26 (m, 12H); 
D15 Yield 68 % 1H NMR (200 MHz, CDCl3) δ  1.42 (s, 9H), 1.80-160 (m, 5H), 2.80-
2.43 (m, 2H),4.22-4.14 (m, 2H), 4.80-4.60 (m, 2H), 7.61-7.34 (m, 18H); 
D16 Yield 77 % 1H NMR (200 MHz, CDCl3) δ  1.42 (s, 9H), 1.80-160 (m, 5H), 2.80-
2.43 (m, 2H),4.22-4.14 (m, 2H), 4.80-4.60 (m, 2H), 7.61-7.34 (m, 14H); 
D17 Yield 56 % 1H NMR (200 MHz, CDCl3) δ  1.42 (s, 9H), 1.80-1.46 (m, 4H), 2.80-
2.42 (m, 2H), 4.20-4.09 (m, 3H), 4.80-4.45 (m, 2H), 7.67-7.10 (m, 13H); 
D18 Yield 30 % 1H NMR (200 MHz, CDCl3) δ  1.41 (s, 9H), 1.80-1.24 (m, 4H), 2.80-
2.21 (m, 2H), 4.20-3.89 (m, 3H), 4.80-4.30 (m, 2H), 7.50-7.30 (m, 14H);  
D19 Yield 39 % 1H NMR (200 MHz, CDCl3) δ  1.42 (s, 9H), 1.80-1.46 (m, 4H), 2.80-
2.42 (m, 2H), 4.20-4.09 (m, 3H), 4.80-4.45 (m, 2H), 7.67-7.10 (m, 13H);  
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General procedure for deprotection reaction 
 
N
boc
N Ar
X
Ar
N
H
N Ar
X
Ar
TFA
DCM
 
Boc-compounds C1-C14  (1.0 eq) were dissolved in a solution of TFA/DCM (4 ml) and 
stirred for 2 hours at room temperature. The desired deprotected products C15 and C16 
were collected after concentration under vacuum and purified  with scx pre-packed 
cartridges. 
C15 Yield 79 % 1H NMR (200 MHz, CDCl3) δ  1.29-0.98 (m, 1H), 1.70-1.44 (m, 3H), 
2.65-2.53 (m, 2H), 3.07 (d, 2H, J= 12.45 Hz), 3.20-3.50 (m, 1H),  4.49 (s, 2H), 7.01-
7.33 (m, 12H), 7.85-7.80 (m, 2H); 
C16 Yield 43 % 1H NMR (200 MHz, CDCl3) δ  0.92-0.76 (m, 2H), 1.68-1.17 (m, 2H), 
2.68-2.55 (m, 2H), 3.21-3.07 (m, 2H), 4.10-3.96 (m, 1H),  4.48 (s, 2H), 7.88-7.15 (m, 
14H); 
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Tetraline Derivative E 
 
Synthesis of compound 23.2 
 
OMeO O
O
OEt
MeO
LHMDS/BrCH2COOEt
HMPA/THF
23.2
22.2  
A THF solution of the commercial available 6-methoxy indanone  22.2 (1.0 eq) was 
added dropwise to LHMDS (1.2 eq) at -60 °C and the mixture was stirred. After 30 
minutes HMPA (1.2 eq) and BrCH2COOEt (2.0 eq) were added and the reaction was 
left under stirring for 1h at -60 °C. After TLC analysis, the mixture was stopped: NH4Cl 
solution was added and the organic layer extracted with AcOEt, dried over Na2SO4 and 
concentrated. The desired product was purified with silica and ionic exchange pre-
packed cartridges.  
Yield 70% 1H NMR (200 MHz, CDCl3) δ  1.22 (t, 3H, J=7.14 Hz), 2.66 (dd, 1H, J=16.8 
and 8.8 Hz), 2.87 (dd, 1H, J=15.22 and 3.91 Hz), 3.09-2.71 (m, 2H), 3.38 (dd, 1H, 
J=16.61 and 7.60 Hz), 3.83 (s, 3H), 4.13 (q, 2H, J=7.14 Hz), 7.37-716 (m, 3H); 
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Synthesis of compound 24.2 
 
NaOH
EtOH O
O
OH
MeOO
O
OEt
MeO
24.223.2  
 
Compound 23.2 (1.0 eq) was diluted in EtOH and a solution of NaOH 2N (10 eq) was 
added. The mixture was stopped after 5h at room temperature with HCl 10% and than 
the organic layer extracted with Et2O, dried over Na2SO4 and concentrated. The desired 
acid was purified with silica and ionic exchange pre-packed cartridges to obtain the 
desire product 24.2. 
Yield 97% 1H NMR (200 MHz, CDCl3) δ 2.64 (dd, 1H, J=17.80 and 9.42 Hz), 2.81 (dd, 
1H, J=16.70 and 3.92 Hz), 3.10-2.97 (m, 2H); 3.42 (dd, 1H, J=16.60 and 7.5 Hz), 3.84 
(s, 3H), 7.38-7.15 (m, 3H); 
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Synthesis of compound 25.2 
NHMe2
O
O
N
MeO
CH3
CH3
O
O
OH
MeO DMF
25.2
24.2  
 
To a stirred solution of carboxylic acid 24.2 (1.0 eq) in dry DMF were added at 0 °C 1-
[3-(dimethylamino)propyl]-3-ethyl-carbodiimide hydrochloride (1.1 eq), 
hydroxybenzotriazole (1.0 eq) and the N,N dimethyl amine (1.1 eq). The solution was 
stirred for 2h. After evaporation of the solvent, the residue was poured into water and 
extracted with AcOEt. The extracts were dried over Na2SO4 and concentrated. The 
residue was purified by column chromatography with AcOEt as eluent.  
Yield 40% 1H NMR (200 MHz, CDCl3) δ 2.63 (dd, 1H, J=17.10 and 9.21 Hz), 2.81 (dd, 
1H, J=16.70 and 3.90 Hz), 2.94 (s, 3H), 3.02 (s, 3H), 3.09-2.97 (m, 2H); 3.41 (dd, 1H, 
J=16.70 and 7.40 Hz), 3.83 (s, 3H), 7. 21-7.14 (m, 2H), 7.33 (d, 1H, J=8.2 Hz); 
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Synthesis of compound 26.2 
 
 
NaBH4
TsOH
Toluene
O
N
MeO
CH3
CH3
O
O
N
MeO
CH3
CH3
1)
2)
26.225.2
 
To a stirred solution of amide 25.2 (1 eq) in MeOH at 0 °C NaBH4 (2.5 eq) was added 
dropwise and the solution was stirred for 1h. After evaporation of the solvent, the 
residue was neutralized with HCl 1N and than extracted with DCM dried over Na2SO4 
and concentrated. The residue was diluted in dry toluene and TsOH (cat) was added and 
the raction was heated to reflux at 120 °C and stirred for 1h . After TLC analysis, the 
mixture was stopped: NaHCO3 solution and brine were added and the organic layer 
were dried over Na2SO4 and concentrated. The crude was used for the next step. 
Yield 65% 1H NMR (200 MHz, CDCl3) δ 2.98 (s, 3H), 3.05 (s, 3H),  3.37 (s, 2H), 3.57 
(s, 2H), 3.81 (s, 1H), 6.57 (bs, 1H), 6.69 (dd, 1H, J=8.01 and 2.38  Hz), 6.99-6.85 (m, 
1H); 7. 28-7.14 (m, 2H); 
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Synthesis of compound 27.2 
 
 
O
N
MeO
CH3
CH3
O
N
MeO
CH3
CH3
H2/Pd/C
27.226.2  
 
To a stirred solution of amide 26.2 (1.0 eq) in EtOH, Pd/C (0.1 eq) was added under 
vacuum and N2 and the mixture was left stirring with H2 for 13h. After TLC analysis, 
the mixture was filtered and the desired product was collected. 
Yield 76% 1H NMR (200 MHz, CDCl3) δ 2.69-246. (m, 4H), 2.96 (s, 3H), 2.98 (s, 3H), 
3.21-2.83 (m, 3H),  3.77 (s, 3H), 6.78-6.66 (m, 2H), 7.08 (d, 1H, J=8.0 Hz); 
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Synthesis of compound 28.2 
 
N
MeO
CH3
CH3
O
N
MeO
CH3
CH3
LiAlH4
THF
28.227.2  
 
To a stirred solution of amide 27.2 (1.0 eq) in dry THF, a solution of LiAlH4 (1.5 eq) 
was added and the mixture was heated to reflux at 70 °C for 1h. After TLC analysis 
water, NaOH were added and the organic layer were dried over Na2SO4 and 
concentrated. The residue was purified by silica and ionic exchange pre-packed 
cartridges.  
Yield 63% 1H NMR (200 MHz, CDCl3) δ 1.76-1.65 (m, 2H), 2.29 (s, 6H), 2.63-2.37 
(m, 4H), 2.84-2.68 (m, 1H),  3.07-2.92 (m, 2H),  3.77 (s, 3H), 6.73-6.64 (m, 2H), 7.06 
(d, 1H, J=8.0 Hz); 
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Synthesis of compound E 
N
MeO
CH3
CH3
BBr3, DCM
N
O
CH3
CH3
Cl
1)
 NaH 60%, DMF2)
28.2 E
 
A solution of BBr3 1M in DCM (3 eq) was added dropwise at -78 °C to a stirred 
solution of amine resulting from sixth step (1.0 eq) in DCM. After 30 minutes the 
mixture was heated to room temperature and left stirring for 1h. After TLC analysis 
NaHCO3 was added and the organic layer were extracted with DCM and dried over 
Na2SO4 and concentrated. The residue was purified by SCX pre-packed cartridges. To a 
stirred solution of alcohol resulting from the previous step (1 eq) in dry DMF at 0 °C 
NaH 60% (2.5 eq) was added and the mixture was heated at 50 °C and stirred for 
1h.The mixture was cooled to 0 °C and than 4-phenylbenzyl chloride (1.1 eq) was 
added and the reaction was stirred at room temperature for 2h. After evaporation of the 
solvent water was added and the organic layer were extracted with AcOEt and dried 
over Na2SO4 and concentrated. The residue was purified by silica and ionic exchange 
pre-packed cartridges.  
Yield 41% 1H NMR (200 MHz, CDCl3) δ 1.46-1.84 (m, 2H), 2.36 (s, 6H), 242-2.66 (m, 
5H), 2.90-3.10 (m, 2H), 5.07 (s, 2H), 6.74-6.88 (m, 2H), 7.08 (d, 1H, J=8.41 Hz), 7.34-
7.63 (m, 9H); 
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Yield 63% 1H NMR (200 MHz, CDCl3) δ 1.65-1.76 (m, 2H), 2.29 (s, 6H), 2.37-2.63 
(m, 4H),  2.68-2.84 (m, 1H),  2.92-3.07 (m, 2H),  3.77 (s, 3H), 6.64-6.73 (m, 2H), 7.06 
(d, 1H, J=8.0Hz); 
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Isoprenoid derivatives F1 and F2 
 
 
Synthesis of compound 30.2 
 
CH3
CH3
O
H
CH3
CH3
O O
DCM
DHP/PPTS
30.229.2  
 
To a DCM solution of the commercial available 3-methyl-2-buten-1-olo (1.0 eq) were 
added 3,4-dihydropyrane (1.5 eq) and PPTs (0.1 eq) and the mixture was stirred for 4h 
at room temperature. After TLC analysis, the reaction mixture was partially evaporated, 
diluted with Et2O and washed with saturated NaHCO3. The organic layer was dried over 
Na2SO4 and concentrated to yield the desired product that was purified with silica and 
ionic exchange pre-packed cartridges.  
Yield 87% 1H NMR (200 MHz, CDCl3) δ  1.85-1.40 (m, 6H), 1.64 (s, 3H), 1.70 (s, 3H), 
3.51-3.40 (m, 1H), 3.86-3.80 (m, 1H), 3.92 (dd, 1H, J=12.10 and 6.02  Hz), 4.17 (dd, 
1H, J=12.10 and 6.02 Hz), 4.58 (t, 1H, J=4.02 Hz), 5.28 (t, 1H, J=6.02 Hz); 
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Synthesis of compound 31.2 
 
tBuOOH/ H2SeO3
Salicilic Acid
DCM
CH3
CH3
O O
CH3
O O
OH
30.2 31.2  
 
Compound 30.2 (1.0 eq) and tert-butyl hydroperoxide (3.20 eq) were stirred in the 
presence of H2SeO3 (0.11 eq) and salicylic acid (0.11 eq) in DCM for 14 h at room 
temperature. The DCM was removed under reduced pressure and tert-butyl 
hydroperoxide was removed by repeated washing with toluene. The residue was 
dissolved in Et2O, washed with NaHCO3 to remove H2SeO3, dried over Na2SO4 and 
concentrated. The residue was purified by silica and ionic exchange pre-packed 
cartridges. 
Yield 40% 1H NMR (200 MHz, CDCl3) δ  1.85-1.54 (m, 9H), 3.57-3.47 (m, 1H), 3.94-
3.83 (m, 1H), 4.10-4.01 (m, 4H), 4.29 (dd, 1H, J=12.10 and 6.42 Hz),4.64 (t, 1H, 
J=3.29 Hz), 5.63 (t, 1H, J=6.10 Hz); 
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Synthesis of compound 32.2 
 
CH3
O O
OH
Cl
CH3
O O
O
DMF/NaH
31.2 32.2
 
Alcohol  31.2 (1.0 eq) was dissolved in dry DMF and cooled to 0 °C prior to NaH 60% 
(2.5 eq) addition and the mixture was heated to 50 °C and stirred. After 1h 4-
phenylbenzyl chloride (1.1 eq) was added at 0 °C and the mixture stirred for 24h at 
room temperature. The reaction mixture was poured over water and extracted with 
AcOEt. The combined extracts were dried over Na2SO4 and concentrated. 
Yield 30% 1H NMR (200 MHz, CDCl3) δ  1.82-1.70 (m, 9H), 3.54-3.48 (m, 1H), 6.9-
3.80 (m,1H), 3.98 (s, 2H), 4.20-4.10 (m, 2H), 4.40-4.24 (m, 1H), 4.52 (s,1                          
H), 4.60 (dd, 2H, J=14.80 and 2.92 Hz), 5.80-5.66 (m, 1H), 7.48-7.33 (m, 5H), 7.62-
7.55 (m, 4H); 
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Synthesis of compound 33.2 
 
CH3
O
HO
CH3
O O
O
PPTs / EtOH 33.232.2
 
To a solution of compound 32.2 (1.0 eq) in EtOH was added PPTs (0.10 eq) and the 
reaction stirred at 55 °C for 6h. The solvent was partially evaporated in vacuo and the 
resulting solution was diluted with Et2O and washed with half-saturated brine to remove 
the catalyst. The organic layer was dried over Na2SO4 and concentrated to yield the 
desired product that was purified with silica and ionic exchange pre-packed cartridges.  
Yield 62% 1H NMR (200 MHz, CDCl3) δ  1.72 (d, 3H, J=7.30), 3.87 (d, 2H, J=18.01), 
4.18 (dd, 2H, J=24.10 and 6.51 Hz), 4.55 (d, 2H, J=7), 5.80-5.66 (m, 1H), 7.48-7.31 (m, 
5H), 7.61-7.56 (m, 4H); 
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Synthesis of compound  F1 and F2 
 
CH3
O
HO
CH3
OO
R
K2CO3/ DMF
Cl NRR
33.2
 
 
The desired alcohol obtained from step four (1.0 eq) was dissolved in dry DMF and 
cooled to 0 °C prior to NaH 60% (2.5 eq) addition and the mixture was heated to 50 °C 
and stirred for 1h. After chloroethyl amine (1.1 eq) was added at 0 °C and the mixture 
stirred for 18-24h at room temperature. The reaction mixture was poured over water and 
extracted with AcOEt. The combined extracts were dried over Na2SO4 and concentrated 
and then purified with silica and ionic exchange pre-packed cartridges (95:5 
CH2Cl2/MeOH) 
F1: Yield 30% 1H NMR (200 MHz, CDCl3) δ  1.25 (s, 2H), 1.70 (d, 3H, J=10.21), 2.3 
(s, 6H), 2.64-2.52 (m, 2H), 3.64-3.47 (m, 2H), 3.94 (d, 1H, J=9.10), 4.13-4.07 (m, 1H), 
4.51 (s, 1H), 4.57 (d, 1H, J=6.70), 5.78-5.64 (m, 1H), 7.48-7.36 (m, 5H), 7.61-7.55 (m, 
4H); 
F2: Yield 25% 1H NMR (200 MHz, CDCl3) δ  1.66-1.2 (m, 6H), 1.70 (d, 4H, J=11.30), 
2.45 (sb, 3H), 2.57 (t, 2H, J=5.91), 3.68-3.50 (m, 2H), 3.93 (d, 1H, J=11.10), 4.10 (t, 2H 
J=6.45), 4.51 (s, 1H), 4.56 (d, 1H, J=4.72), 5.74-5.64 (m, 1H), 7.48-7.33 (m, 5H), 7.61-
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Carbazole Derivatives 
 
Synthesis of carbazole derivatives  
Generic synthetic procedure for reaction with epichloridrin 
N
H
R3
R3
Cl O
N
O
R3
R3
KOH/DMF
36.2 R3= H 
40.2 R3=Cl
 
The carbazole (1.0 eq) was diluted in DMF and the KOH (1.2 eq) was added. The 
reaction was left under stirring for 1h at room temperature and after cooled -10 °C. The 
cooled resulting mixture was added very slowly to a mixture of the epichloridrin (2.5 
eq) in DMF anhydrous and left under stirring for 4-6 hours. The reaction was stopped 
after TLC analysis: the mixture was threw to ice water and extracted with AcOEt and 
after dried over Na2SO4 and concentrated.The resulting products (36.2 and 40.2 ) have 
been purified with silica and ionic exchange pre-packed cartridges.  
36.2 Yield 50% 1H NMR (200 MHz, CDCl3) δ 2.57 (dd, 1H, J=4.76 and 2.56 Hz), 2.81 
(ps t,1H, J=4.29 Hz) , 3.39-3.32 (m, 1H), 4.40 (dd, 1H J=15.75 and 4.71 Hz), 4.63 (dd, 
1H J=15.75 and 3.29 Hz), 7.30-7.22 (m, 2H),7.49-7.46 (m, 4H), 8.10( d, 1H, J=7.87 );  
40.2 Yield 50% 1H NMR (200 MHz, CDCl3) δ 2.52(dd, 1H, J=4.76 and 2.75 Hz), 2.81 
(ps t,1H, J=4.02 Hz) , 3.37-3.28 (m, 1H), 4.29 (dd, 1H J=16.11 and 5.30 Hz), 4.66 (dd, 
1H J=15.90 and 2.74 Hz), 7.47-7.36 (m, 6H), 7.99-7.97 (m, 2H);  
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  General procedure for ring opening reaction 
N
O
R3
R3
N
N
OHAr
R3
R3
36.2 R3= H 
40.2 R3=Cl
37.2a-f R3=H
38.2 a-d R3=H
40.2a R3=Cl  
Procedure 1 
To a mixture of epoxide (1.0 eq) in EtOH (heating at 50 °C is soluble) the amine (2.0 
eq) was added and the reaction was heated to reflux overnight. The solvent was 
evaporated and the product was purified with silica and ionic exchange pre-packed 
cartridges.  
Procedure 2 
To a mixture of epoxide (1.0 eq) in ciclohexane at r.t. the amine (1.20 eq) and BiCl3 
(0.10 eq) were added and the reaction was left under stirring for 2-4 hours. The reaction 
was stopped: NaHCO3 was added and the mixture extracted with DCM and than dried 
over Na2SO4 and concentrated. The products were purified with silica and ionic 
exchange pre-packed cartridges.  
37.2a Yield 40% 1H NMR (200 MHz, CDCl3) δ 2.17-2.15 (m, 1H), 3.44-3.22 (m,2H), 
4.47 (s, 2H), 6.78-6.61 (m, 3H),7.29-7.14 (m, 4H), 7.48-7.44 (m, 4H), 8.11 (d, 2H, 
J=7.69Hz); 
37.2b Yield 68% 1H NMR (200 MHz, CDCl3) δ 2.17-2.15 (m, 1H), 3.44-3.22 (m,3H), 
4.46 (s, 2H), 6.74 (AA’/XX’, 2H, JAX=8.7 and JAA’/XX’=2.5 Hz), 7.11 (AA’/XX’, 2H, 
JAX=8.7 and J AA’/XX’=2.5 Hz), 7.30-7.22 (m, 4H),   7.46 (d, 4H, J=3.66 Hz),  8.11 (d, 
2H, J=7.69Hz); 
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37.2c Yield 63% 1H NMR (200 MHz, CDCl3) δ  2.23 (s, 3H), 3.20 (dd, 1H, J=6.4 and 
12.8 Hz), 3.34 (dd, 1H, J=3.48 and 12.8 Hz), 4.4-4.5 (m,4H), 6.55 (AA’/XX’, 2H, 
JAX=8.4 and JAA’/XX’=2.2 Hz), 6.98(AA’/XX’, 2H, JAX=8.4 and JAA’/XX’=2.5 Hz), 7.21-
7.29 (m,2H), 7.41-7.47 (m, 4H), 8.1(d, 2H, J=7.69 Hz); 
37.2d Yield 43% 1H NMR (200 MHz, CDCl3) δ  2.17-2.15 (m, 1H ), 3.36-3.16 (m, 2H), 
4.46 (s, 2H), 6.58-6.52 (m, 2H), 6.92-6.83 (m, 2H), 7.29-7.22 (m, 2 H), 7.46 (d, 4H, 
J=3.6 Hz), 8.11 (d, 2H, J=7.87 Hz); 
37.2e Yield 71% 1H NMR (200 MHz, CDCl3) δ  3.50-3.20 (m,2H), 4.42-4.36 (m,1H), 
4.54-4.44 (m,2H), 6.61 (d, 2H, J=8.6 Hz), 7.47-7.23 (m, 8H), 8.11(d, 2H, J=7.69 Hz); 
37.2f Yield 55% 1H NMR (200 MHz, CO(CD3)2 δ  2.07-2.02 (m,2H), 3.56-3.44 
(m,2H), 4.67-4.48 (m, 5H), 6.77-6.74 (m, 2H), 7.19 (t, 2H J=7.15 Hz), 7.41 (t, 2H 
J=7.53 Hz), 7.62 (d, 2H J=8.00 Hz), 8.00 (d, 2H, J=9.30 Hz);8.13(d, 2H, J=7.51 Hz); 
38.2a Yield 56% 1H NMR (200 MHz, CDCl3) δ 2.67 (dd, 1H, J=8.20 and 1.200 Hz), 
2.83 (dd, 1H, J=3.50 and 12.00 Hz), 3.73 ( AB quartet, 2H, J=13 Hz), 4.28-4.16 
(m,1H), 4.36 (s,1H), 4.39 (d, 1H, J=2.38 Hz),7.31-7.20 (m, 7H), 7.46( d, 4H, J=4.39 Hz 
), 8.09 (d, 2H, J=7.69 Hz); 
38.2b Yield 44% 1H NMR (200 MHz, CDCl3) δ 2.64 (dd, 1H, J=8.04 and 12.00 Hz), 
2.8 (dd, 1H, J=3.60 and 12.00 Hz), 3.69 (AB quartet, 2H, J=13.01 Hz), 4.26-4.14 (m, 
1H), 4.37(s,1H), 4.40 (d, 1H, J=2.56 Hz), 7.26-7.16 (m, 6H), 7.46 (d, 4H, J=3.67 Hz), 
8.09 (d, 2H, J=7.87 Hz); 
38.2c Yield 70% 1H NMR (200 MHz, CDCl3) δ 2.47 (s,3H), 2.78 (dd, 1H, J = 8.32 and 
12.01 Hz), 2.92 (dd, 1H, J=3.61 and 12.01 Hz), 3.82 (AB quartet, 2H, J=13.01 Hz) 
4.37-4.26 (m, 1H), 4.50 (s,1H), 4.53 (d, 1H, J=2.02 Hz), 7.41-7.35 (m, 6H), 7.60 (d, 4H, 
J=3.66 Hz), 8.23 (d, 2H, J=7.87 Hz); 
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38.2d Yield 47% 1H NMR (200 MHz, CDCl3) δ 2.63 (dd, 1H, J=8.3 and 12 Hz), 2.8 
(dd, 1H, J=3.60 and 12.00 Hz), 3.65 (AB quartet, 2H, J=13.01 Hz), 3.79 (s,3H), 4.23-
4.11 (m, 1H), 4.37-4.35(m,1H), 4.39 (d, 1H, J=2.41 Hz), 6.83 (AA’/XX’, 2H, JAX=8.60 
and JAA’/XX’=2.50 Hz), 7.14 (AA’/XX’, 2H, JAX=8.60 and JAA’/XX’=2.50 Hz), 7.28-7.21 
(m, 2H), 7.46 (d, 4H, J=4.40 Hz), 8.09 (d, 2H, J=7.64 Hz); 
41.2a Yield 73% 1H NMR (200 MHz, CDCl3) δ 2.58 (dd, 1H, J=12.00 and 8.30 Hz), 
2.81 (dd, 1H, J=12.00 and 3.84 Hz), 3.73 (d, 2H, J=3.10 Hz), 4.16-4.06 (m,1H), 4.32 (d, 
2H, J=5.49 Hz), 7.40-7.27 (m, 9H), 8.20-7.97 (m, 2H ); 
L Yield 70% 1H NMR (200 MHz, CDCl3) δ  2.30-2.21 (m, 1H), 3.40 (dd, 1H, J=12.60 
and 6.49 Hz), 3.54 (dd, 1H, J=12.60 and 3.10 Hz), 4.74-4.55 (m, 3H), 6.57 (dd, 1H, 
J=5.78 and 2.60 Hz) 7.31-7.22 (m, 4H), 7.53-7.42 (m, 6 H), 7.85-7.76 (m, 2H), 8.12 (d, 
2H, J=7.69 Hz); 
M Yield 64 %  1H NMR (200 MHz, CDCl3) δ 3.36 (dd, 1H, J = 3.84 and 12.0 Hz),  
3.55-3.48 (m, 1H), 4.58-4.47 (m, 3H),  6.57-6.52 (m, 1H),  7.32-7.28 (m, 3H), 7.51-7.41 
(m, 6H),  7.86-7.79 (m, 2H), 7.99-8.02 (m, 1H ); 
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Generic synthetic procedure for cupping reaction with sulfonil and acyl chlorides 
 
N
N
OHAr
R3
R3
X=SO2, CO
N
OH
NX R1
R2
R3
R3
R'
37.2a-f 
38.2 a-d
40.2a
R1,R2=
R3= H,Cl
 
 
For each amine : To a solution of the amine (1.0 eq) in DCM the various sulfonil and 
acyl chlorides (1.0-1.50 eq) were added and after DMAP (cat) and PS–DIEA (1.20 eq) 
were added. The reaction mixtures were stirred at room temperature overnight and than 
filtered and evaporated and purified with silica and ionic exchange pre-packed 
cartridges. 
G1 Yield 66 % 1H NMR (200 MHz, CDCl3) δ 2.22 (s, 1H), 3.71-3.69 (m, 2H), 4.30-
4.23 (m, 2H), 4.54-4.51 (m, 1H), 7.35-7.08 (m, 2H), 7.24-7.19 (m, 2H), 7.35-7.31 (m, 
5H), 7.42-7.38 (m, 6H), 8.10 (d, 2H, J=7.69Hz); 
G2 Yield 46 % 1H NMR (200 MHz, CDCl3) δ 2.26-2.15 (m, 1H), 3.73-3.71 (m, 2H), 
3.68 (s, 3H),  4.39-3.86 (m, 2H), 4.54-4.50 (m, 1H), 6.88 (d, 2H, J=7.69Hz), 7.09-7.05 
(m, 2H), 7.25-7.21 (m, 3H), 7.35-7.32 (m, 5H), 7.46-7.42 (m, 4H), 8.06 (d, 2H, 
J=7.69Hz); 
G3 Yield 57 % 1H NMR (200 MHz, CDCl3) δ  2.24-2.19 (m, 1H), 3.73 (d, 4H, J=5.31 
Hz), 4.46 (s, 3H), 4.54-4.20 (m, 4H), 7.69-7.21 (m, 15H), 8.08 (d, 2H, J=7.69 Hz); 
G4 Yield 66 % 1H NMR (200 MHz, CDCl3) δ  3.69 (d, 2H, J=6.20 Hz), 4.56-4.20 (m, 
4H), 6.98 (d, 2H, J = 8.42 Hz), 7.59-7.21 (m, 13H), 8.07 (d, 2H, J=7.87 Hz); 
G5 Yield 18 % 1H NMR (200 MHz, CDCl3) δ  2.24-2.19 (m, 1H), 3.73 (d, 4H, J=5.31 
Hz), 4.54-4.20 (m, 4H), 7.60-7.15 (m, 15H), 8.06 (d, 2H, J=7.69 Hz); 
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G7 Yield 77% 1H NMR (200 MHz, CDCl3) δ  3.72-3.68 (m, 2H), 4.56-4.23 (m, 3H), 
7.02- 6.97 (m, 4H), 7.59-7.19 (m, 11H), 8.04 (d, 2H, J = 7.69 Hz); 
H1 Yield 57% 1H NMR (200 MHz, CDCl3) δ  3.91 (dd, 1H, J=14.00 and 2.43 Hz), 4. 
51-4.28 (m, 5H), 6.92-6.88 (m, 2H), 7.29 -7.05 (m, 10 H), 7.43 (d, 4H, J=3.81 Hz), 8.06 
(d, 2H, J=7.69 Hz); 
H2 Yield 57% 1H NMR (200 MHz, CDCl3) δ  3.64-3.61 (m, 1H),  3.92-3.88 (m, 1H),  
4.39-4.23 (m, 2H),  4.48-4.47 (m, 1H), 6.90-6.86 (m, 2H), 7.11-7.08 (m, 4 H), 7.24 -
7.17 (m, 4 H), 7.43-7.41 (m, 4H), 8.05 (d, 2H, J=7.69 Hz); 
H3 Yield 57% 1H NMR (200 MHz, CDCl3) δ  3.70 (s, 3H),  3.88-3.84 (m, 1H),  4.11-
4.05 (m, 3H), 4.46-4.39 (m, 3H), 6.63-6.54 (m, 2H), 6.90-6.87 (m, 2H), 7.09-7.05 (m, 
3H), 7.24 -7.22 (m, 4 H), 7.41-7.39 (m, 4H), 8.04 (d, 2H, J=7.69 Hz); 
H4 Yield 40 % 1H NMR (200 MHz, CDCl3) δ  3.43-3.41 (m, 1H),  3.92-3.88 (m, 1H), 
4.18-4.09 (m, 1H), 4.38-4.35 (m, 2H), 4.48-4.43 (m, 1H), 6.97-6.90 (m, 3H), 7.14-7.12 
(m, 4H), 7.25 -7.21 (m, 2 H), 7.47-7.39 (m, 5H), 8.05 (d, 2H, J=7.69 Hz); 
H5 Yield 65% 1H NMR (200 MHz, CDCl3) 2.25(s, 3H), 3.62-3.42 (m, 2H), 3.93 (d, 1H, 
J=14.10 Hz), 4.22 (dd, 1H, J=714. and 10.75 Hz), 4.26-4.20 (m,4H), 6.88 (d, 2H, 
J=8.05 Hz), 7.27-7.13 (m,6H), 7.52-7.36 (m, 5H), 8.06 (d, 2H, J=8.05 Hz); 
H6 Yield 43% 1H NMR (200 MHz, CDCl3) δ  2.30-2.21(m, 1H), 3.65 (d, 1H, J=3.6 
Hz), 3.83 (dd, 1H, J=14.10 and 2.22 Hz), 4.24 (dd, 1H, J=14.10 and 7.70 Hz), 4.50-4.41 
(m, 3H), 6.57 (dd, 1H, J=5.78 and 2.60 Hz), 6.75 (AA’/XX’, 2H, JAX=8.70 and 
JAA’/XX’=2.51 Hz), 6.98 (AA’/XX’, 2H, JAX=8.70 and J AA’/XX’=2.51 Hz) 7.31-7.22 (m, 
4H), 7.26-7.16 (m, 6 H), 7.44-7.14 (m, 5H), 8.06 (d, 2H, J=7.69 Hz); 
H7 Yield 65% 1H NMR (200 MHz, CDCl3) 3.62-3.42 (m, 2H), 3.93 (d, 1H, J=14.10 
Hz), 4.22 (dd, 1H, J=714. and 10.75 Hz), 4.260-4.20 (m,4H), 6.88 (d, 2H, J=8.05 Hz), 
7.27-7.13 (m,6H), 7.52-7.36 (m, 5H), 8.06 (d, 2H, J=8.05 Hz); 
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H8 Yield 80% 1H NMR (200 MHz, CDCl3) δ  ), 3.97 (dd, 1H, J=14.46 and 2.19 Hz), 
4.23-4.12 (m, 1H), 4.58-4.41 (m, 3H), 6.84 (AA’/XX’, 2H, JAX=9.15 and J AA’/XX’=2.30 
Hz), 7.28-7.17 (m, 7H), 7.44-7.41 (m, 4H), 7.77 (AA’/XX’, 2H, JAX=9.15 and J 
AA’/XX’=2.30 Hz), 8.02 (d, 2H, J=7.69 Hz); 
H9 Yield 80% 1H NMR (200 MHz, CDCl3) δ  3.74-3.66 (m, 1H), 3.81 (dd, 1H, J=2.30 
and 14.0 Hz), 4.28 (dd, 1H, J=14.0 and 8.0 Hz), 4.58-4.41 (m, 3H), 6.86-6.68 (m, 5H), 
7.27-7.14 (m, 6H), 7.44 (d, 4H, J=3.48 Hz), 8.06 (d, 2H, J=7.87 Hz); 
J1 Yield 59% 1H NMR (200 MHz, CDCl3) δ  3.63-2.65 (m, 1H), 3.09 (dd, 1H, J=14.90 
and 3.70 Hz), 3.3 (dd, 1H, J=14.70 and 7.60 Hz), 4.15 (d, 4H, J=6.59 Hz), 4.20 (AB 
quartet, 2H, J=14.10 Hz),7.94-7.62 (m, 16 H), 7.80 (d, 2H, J=7.69 Hz), 8.06 (d, 2H, 
J=7.69 Hz); 
J2 Yield 56%  1H NMR (400 MHz) CDCl3: δ 8.06 (d, 2H, J= 7.2 Hz), 7.68 (d, 2H, J= 
8.4 Hz), 7.39 (td, 2H, J= 7.7, 1.0 Hz), 7.30 (d, 2H, J= 7.6 Hz), 7.28-7.00 (m, 10 H), 4.35 
(d, 1H, J= 14 Hz), 4.15 (d, 2H, J= 6.4 Hz), 4.00 (d, 2H, J= 14 Hz), 3.28 (dd, 1H, J= 
14.8, 8.0 Hz), 3.08 (dd, 1H, J= 15.4, 3.8  Hz), 2.67 (m, 1H), 2.44 (m, 3H).    
J3 Yield 38%   1H NMR (400 MHz) CDCl3: δ 8.07 (d, 2H, J= 7.6 Hz), 7.69 (d, 2H, J= 
8.8 Hz), 7.50-7.35 (m, 4H), 7.30-7.10 (m, 6H), 7.13-7.04 (m, 2H), 4.33 (d, 1H, J= 14.4 
Hz), 4.17-4.03 (m, 4H), 3.30-3.27 (m, 1H), 3.25-3.08 (m, 1H), 2.53-2.52 (m, 1H). 
J4 Yield 20%   1H NMR (400 MHz) CDCl3: δ 8.05 (d, 2H, J= 7.6 Hz), 7.72 (d, 2H, J= 
8.8 Hz), 7.38 (t, 2H, J= 7.6 Hz), 7.37-7.09 (m, 7H), 7.04-6.80 (m, 4H), 4.32 (d, 1H, J= 
14 Hz), 4.17-4.10 (m, 2H), 4.08-4.00 (m, 2H), 3.87 (s, 3H), 3.29-3.23 (m, 1H), 3.08-
3.03 (m, 1H), 2.71-2.70 (m, 1H). 
J5 Yield 40% 1H NMR (200 MHz, CDCl3) δ  2.24 (s, 3H), 3.08 (dd, 1H, J=1.50 and 
3.50 Hz), 3.29 (dd, 1H, J=15.0 and 7.70 Hz), 4.15 (d, 2H, J=6.20 Hz), 4.37-4.34(m,1H), 
 151 
4.15 (AB quartet, 2H, J=13.90 Hz), 6.88-6.87 (m,4H), 7.26-7.15 (m,4H), 7.61-7.35 (m, 
5H), 7.8 (d, 2H, J=8.20 Hz), 8.06 (d, 2H, J=7.69 Hz); 
J6 Yield 73% 1H NMR (200 MHz, CDCl3) δ  2.84 (d, 1H, J=2.56 Hz), 3.03 (dd, 1H, 
J=15.0 and 3.0 Hz), 3.32 (dd, 1H, J=15.0 and 8.1 Hz), 4.09-3.96 (m,1H), 4.22-4.16 
(m,2H), 4.13 (AB quartet, 2H, J=14.30 Hz), 6.84(AA’/XX’, 2H, JAX=8.40 and 
JAA’/XX’=2.1 Hz), 6.98(AA’/XX’, 2H, JAX=8.40 and JAA’/XX’=2.1 Hz), 7.27-7.14 (m, 4H), 
7.62-7.36 (m, 5H), 7.80 (d, 2H, J=6.70 Hz), 8.07 (d, 2H, J=7.69 Hz); 
J7 Yield 86% 1H NMR (200 MHz, CDCl3) δ  2.72 (d, 1H, J =2.91 Hz), 3.08 (dd, 1H, 
J=15.0 and 3.50 Hz), 3.29 (dd, 1H, J=15.0 7 and.69 Hz), 3.73 (s,3H), 4.13 (AB quartet, 
2H, J=14.01 Hz), 4.17 (d, 2H, J=6.59), 6.60 (AA’/XX’, 2H, JAX=8.50and JAA’/XX’=2.20 
Hz), 6.91(AA’/XX’, 2H, JAX=8.50 and JAA’/XX’=2.50 Hz), 7.24-7.15 (m,5H), 7.62-7.35 
(m, 6H), 7.8 0(d, 2H, J=8.50 Hz), 8.06 (d, 2H, J=7.69 Hz); 
J8 Yield 71% 1H NMR (200 MHz, CDCl3) δ  2.72 (d, 1H, J=3.10 Hz), 3.03 (dd, 1H, 
J=14.50 and 3.70 Hz), 3.24 (dd, 1H, J=14.50 and 7.40 Hz), 3.95-3.80 (m, 1H), 4.19 (AB 
quartet, 2H, J=14.0 Hz), 7.19-7.04 (m, 7H), 7.34 (dd, 2H, J=1.90 and 8.69 Hz ), 7.65-
7.52 (m, 3H), 7.81 (d, 2H, J=7.30 Hz), 7.95 (d, 2H, J=1.80 Hz); 
J9 Yield 73% 1H NMR (200 MHz, CDCl3) δ  2.46 (s, 3H), 2.77 (d, 1H, J=3.10 Hz), 
3.08 (dd, 1H, J=15.0 and 3.75 Hz), 3.21(dd, 1H, J=15.0 and 7.69 Hz), 4.13 0-3.85 (m, 
3H), 4.11 (AB quartet, 2H, J=14.0 Hz), 7.04 (AA’/XX’, 2H, JAX=8.45 and JAA’/XX’=2.20 
Hz), 7.17-7.12 (m, 5H), 7.37-7.31 (m, 4H), 7.68 (AA’/XX’, 2H, JAX=8.45 and 
JAA’/XX’=2.20 Hz), 7.94 (d, 2H, J=1.80 Hz); 
J10 Yield 56% 1H NMR (200 MHz, CDCl3) δ  2.46 (s, 3H), 2.62 (m,1H), 3.03 (dd, 1H, 
J=14.70 and 3.10 Hz), 3.22 (dd, 1H, J=14.70 and 7.0 Hz), 3.98-3.84 (m, 1H), 4.13-4.02 
(m, 2H), 4.19 (AB quartet, 2H, J=13.70 Hz), 7.02 (m, 9H), 7.51 (AA’/XX’, 2H, 
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JAX=8.50 and JAA’/XX’=1.90 Hz), 7.72 (AA’/XX’, 2H, JAX=8.50 and JAA’/XX’=1.90 Hz), 
7.98-7.91 (m, 2H); 
J11 Yield 43% 1H NMR (200 MHz, CDCl3) δ  2.79 (d, 1H, J=2.70 Hz), 2.97 (dd, 1H, 
J=14.80 and 3.70 Hz), 3.19 (dd, 1H, J=7.69 and 14.80 Hz), 3.89 (s, 3H), 4.14-3.93 (m, 
3H), 4.19 (AB quartet, 2H, J=12.50 Hz), 6.99 (AA’/XX’, 2H, JAX=8.80 and 
JAA’/XX’=2.00 Hz), 7.16-7.05 (m, 7H), 7.34 (dd, 2H, J=8.70 and 2.00 Hz), 7.71 
(AA’/XX’, 2H, JAX=8.80 and JAA’/XX’=2.0 Hz), 7.94 (d, 2H, J=2.01 Hz); 
K1 Yield 90% 1H NMR (200 MHz, CDCl3) δ 3.28 (d, 1H, J=14.50 Hz), 4.29-3.86 (m, 
1H), 4.40-4.26 (m, 5H) 6.76-6.64 (m, 2H), 7.10-6.94 (m, 2H), 7.46-7.20 (m, 12 H), 8.08 
(d, 2H, J=7.69 Hz); 
K2 Yield 48% 1H NMR (200 MHz) CDCl3: δ 8.08 (d, 2H, J= 7.5 Hz), 7.46-7.00 (m, 
13H), 6.80-6.65 (m, 2H), 4.45-4.13 (m, 5H), 3.94-3.86 (m, 1H), 3.30 (d, 1H, J= 13.9 
Hz); 
K3 Yield 30% 1H NMR (200 MHz) CDCl3: δ 8.07 (d, 2H, J= 7.6 Hz), 7.45-7.19 (m, 
7H), 7.10-6.90 (m, 3H), 6.87-6.73 (m, 5H), 4.40-4.13 (m, 5H), 4.05-3.80 (m, 1H), 3.80 
(s, 3H), 3,25 (d, 1H, J= 13.9 Hz); 
K4 Yield 74% 1H NMR (200 MHz) CDCl3: δ 8.08 (d, 2H, J= 7.6 Hz), 7.52-7.10 (m, 
12H), 6.80-6.60 (m, 2H), 4.30-3.83 (m, 6H), 3.36 (d, 1H, J= 13.7 Hz); 
K5 Yield 57% 1H NMR (200 MHz, CDCl3) δ  2.21 (s, 3H), 3.26 (d, 1H, J=13.90 Hz), 
4.40- 3.90 (m,5H), 6.55 (AA’/XX’, 2H, JAX=8.24 and JAA’/XX’=2.20 Hz), 6.75 
(AA’/XX’, 2H, JAX=8.24 and JAA’/XX’=2.20 Hz), 7.46-7.23 (m, 11H), 8.08 (d, 2H, 
J=7.69 Hz); 
K6 Yield 73% 1H NMR (200 MHz, CDCl3) δ  3.18 (d, 1H, J=14.50 Hz), 4.40-3.84 
(m,1H), 4.37-4.15 (m,4H), 6.54 (AA’/XX’, 2H, JAX=8.30 and JAA’/XX’=2.40 Hz), 6.89 
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(AA’/XX’, 2H, JAX=8.30 and JAA’/XX’=2.40 Hz), 7.47-7.21 (m, 11H), 8.09 (d, 2H, 
J=7.69 Hz); 
K7 Yield 73% 1H NMR (200 MHz, CDCl3) δ  3.23 (d, 1H, J =14.46 Hz), 3.72 (s,3H), 
4.04-3.9 (m, 1H), 4.34-4.16 (m, 4H), 6.60-6.45 (m, 4H), 7.47-7.20 (m, 11H), 8.08 (d, 
2H, J = 7.69 Hz); 
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Synthesis of  indole derivatives 
Generic synthetic procedure for  reaction with epichloridrin  
 
Cl O
KOH/DMFN
H
R
R'
N
R
R'
O
44 R=H,R'=H            
45 R=H, R'=Ph         
46 R=OMe, R'=Ph  
      
48 R=H,R'=H            
49 R=H,R'=Ph         
50 R=OMe, R'=Ph   
     
 
For each indole: 
The indole (1.0 eq) was diluted in DMF and the KOH (1.2 eq) was added. The reaction 
was left under stirring for 1h at room temperature and after cooled -10 °C. The cooled 
resulting mixture was added very slowly to a mixture of the epichloridrin (2.5 eq) in 
DMF anhydrous and left under stirring for 4-6 hours. The reaction was stopped after 
TLC analysis: the mixture was threw to ice water and extracted with AcOEt and after 
dried over Na2SO4 and concentrated. The resulting products have been purified with 
silica and ionic exchange pre-packed cartridges.  
48 Yield 54 %  1H NMR (200 MHz) CDCl3: δ 7.65 (d, 1H, J= 7.5 Hz), 7.39 (d, 1H, J= 
8.19 Hz), 7.28-7.09 (m, 3H), 6.52 (dd, 1H, J=3.11, 0.73 Hz), 4.44 (dd, 1H, J= 15.3 and 
3.2 Hz), 4.19 (dd, 1H, J= 15.2 and 5.12 Hz), 3.33-3.25 (m, 1H), 2.81 (ψ t, 1H, J= 4.2 
Hz), 2.46 (dd, 1H, J= 4.6 and 2.6 Hz); 
49 Yield >90 % 1H NMR (200 MHz, CDCl3) δ  2.40 (dd, 1H, J=4.76 and 2.56 Hz), 2.74 
(ps triplet, 1H, J=4.31 Hz), 3.17-3.25 (m, 1H), 4.26 (dd, 1H, J=15.56 and 4.57 Hz), 4.39 
(dd, 1H, J=15.56 and 3.84 Hz), 6.58(s, 1H), 7.31-7.12 (m, 2H); 7.65-7.41 (m, 7H); 
50 Yield 60% 1H NMR (200 MHz, CDCl3) δ  2.39 (dd, 1H, J=4.76 and 2.50 Hz), 2.73 
(ps triplet, 1H, J=4.76 Hz), 3.22-3.15 (m, 1H), 3.87 (s, 3H), 4.22 (dd, 1H, J=15.5 and 
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4.70 Hz), 4.36 (dd, 1H, J=15.5 and 3.60 Hz), 6.5 (s, 1H), 6.91 (dd, 1H, J=8.80 and 2.40 
Hz), 7.12 (d, 1H, J=2.30), 7.54-7.36 (m, 6H); 
 
General procedure for ring opening reaction  
 
BiCl3
NH2
Cyclo hexane
N
R
R'
O
N
R
R'
OH
NH
48 R=H,R'=H            
49 R=H,R'=Ph         
50 R=OMe, R'=Ph   
     
N R=H,R'=H           
O  R=H, R'=Ph         
P  R=OMe, R'=Ph   
     
 
 
Procedure 1 
To a mixture of epoxide (1.0 eq) in EtOH (heating at 50 °C is soluble) the α-
naphtylamine (1.0-4.0 eq) was added and the reaction was heated to reflux overnight. 
The solvent was evaporated and the products were purified with silica and ionic 
exchange pre-packed cartridges.  
Procedure 2 
To a mixsture of epoxide (1.0 eq) in ciclohexane at room temperature the α-
naphtylamine (1.20 eq) and BiCl3 (0.10 eq) were added and the reaction was left under 
stirring for 2-4 hours. The reaction was stopped: NaHCO3 was added and the mixture 
extracted with DCM and than dried over Na2SO4 and concentrated. The products were 
purified with silica and ionic exchange pre-packed cartridges.  
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N Yield 55%  1H NMR (200 MHz) CDCl3: δ 7.80 (m, 2H), 7.66 (d, 1H, J= 7.8 Hz), 
7.50-7.10 (m, 8H), 6.62-6.50 (m, 2H), 4.66 (s, 1H), 4.45-4.24 (m, 3H), 3.51-3.43 (m, 
2H), 3.28 (dd, 1H, J=12.7 and 6.8 Hz), 2.21 (s, 1H); 
O Yield 57% 1H NMR (200 MHz, CDCl3) δ 3.04 (dd, 1H, J=12.80 and 6.70 Hz),  3.24 
(dd, 1H, J=12.80 and 3.66 Hz), 4.58-4.26 (m, 3H), 6.60 (s, 1H), 7.30-7.14 (m, 4H ), 
7.59-7.38 (m, 11H ), 7.76-7.64 (m,1H ), 7.79-7.74 (m, 1H); 
P Yield 57% 1H NMR (200 MHz, CDCl3) δ  3.1 (dd, 1H, J=12.60 and 6.71 Hz), 2.26-
2.45 (m, 3H), 3.66 (dd, 1H, J=12.60 and 3.10 Hz), 3.88 (s, 3H), 6.37 (dd, 1H, J=5.67 
and 2.90 Hz), 6.52 (s, 1H), 6.92 (dd, 1H, J=8.80 and 2.40 Hz), 7.12 (d, 1H, J=2.40 Hz); 
7.58-7.31 (m,1H ), 7.79-7.73 (m, 1H); 
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